

1 Cell-wall synthases contribute to 2 bacterial cell-envelope integrity by 3 actively repairing defects

4 **Antoine Vigouroux^{1,2,3}, Baptiste Cordier¹, Andrey Aristov¹, Enno Oldewurtel¹,**
5 **Gizem Özbaykal^{1,4}, Thibault Chaze⁵, Mariette Matondo⁵, David Bikard², Sven van**
6 **Teeffelen^{1*}**

*For correspondence:

sven.vanteeffelen@gmail.com (SVT)

7 ¹Microbial Morphogenesis and Growth Laboratory, Institut Pasteur, Paris, France;
8 ²Synthetic Biology Laboratory, Institut Pasteur, Paris, France; ³Université Paris Descartes,
9 Sorbonne-Paris-Cité, Paris, France; ⁴Université Paris Diderot, Sorbonne-Paris-Cité, Paris,
10 France; ⁵Proteomics Platform, Institut Pasteur, Paris, France

11
12 **Abstract** Cell shape and cell-envelope integrity of bacteria are determined by the peptidoglycan
13 cell wall. In rod-shaped *Escherichia coli*, two conserved sets of machinery are essential for cell-wall
14 insertion in the cylindrical part of the cell, the Rod complex and the class-A penicillin-binding
15 proteins (aPBPs). While the Rod complex governs rod-like cell shape, aPBP function is less well
16 understood. aPBPs were previously hypothesized to either work in concert with the Rod complex
17 or to independently repair cell-wall defects. First, we demonstrate through modulation of enzyme
18 levels that class-A PBPs do not contribute to rod-like cell shape but are required for mechanical
19 stability, supporting their independent activity. By combining measurements of cell-wall stiffness,
20 cell-wall insertion, and PBP1b motion at the single-molecule level we then demonstrate that PBP1b,
21 the major class-A PBP, contributes to cell-wall integrity by localizing and inserting peptidoglycan in
22 direct response to local cell-wall defects.

24 Introduction

25 The peptidoglycan cell wall is responsible for both cell shape and mechanical integrity of the
26 bacterial cell envelope (*Typas et al., 2010; Vollmer and Bertsche, 2008*). In Gram-negative bacteria
27 such as *E. coli* the cell wall is a thin two-dimensional polymer that consists of parallel glycan strands
28 oriented circumferentially around the cell axis (*Gan et al., 2008*) and peptide cross-links that connect
29 adjacent glycan strands. To avoid the formation of large pores in the cell wall during growth, cell-wall
30 insertion and cell-wall cleavage must be tightly coordinated (*Vollmer et al., 2008*).

31 Cell-wall insertion involves two kinds of enzymatic reactions: transglycosylase (TGase) activity to
32 extend the glycan strands, and transpeptidase (TPase) activity to create cross-links between glycan
33 strands. During side-wall elongation these two activities are carried out by two sets of machinery
34 (*Cho et al., 2016*). First, the Rod complex comprises the Penicillin-Binding Protein PBP2, an essential
35 transpeptidase (TPase), and RodA, an essential transglycosylase (TGase) and member of the SEDS
36 (shape, elongation, division and sporulation) family of proteins (*Meeske et al., 2016; Emami et al.,*
37 *2017*). Together with the MreB cytoskeleton these and other Rod-complex components persistently
38 rotate around the cell (*Lee et al., 2014; Cho et al., 2016*) and are responsible for rod-like cell shape.
39 Second, bi-functional and essential class-A PBPs (aPBPs) PBP1a and PBP1b carry out both TPase and
40 TGase activities. PBP1a and PBP1b are activated by the outer-membrane lipoprotein cofactors LpoA

41 and LpoB, respectively (*Typas et al., 2010; Paradis-Bleau et al., 2010; Typas et al., 2012*). Mutants
42 in either PBP1a-LpoA or PBP1b-LpoB are viable and don't show any strong phenotype during
43 regular growth, but mutants in components from both pairs are synthetically lethal (*Yousif et al.,*
44 *1985; Typas et al., 2010; Paradis-Bleau et al., 2010*). aPBPs also interact with cell-wall cleaving lytic
45 transglycosylases and DD-endopeptidases (*Banzhaf et al., 2019*), consistent with the possibility that
46 they form multi-enzyme complexes responsible for both cell-wall expansion and insertion.

47 In the past, aPBPs have been suggested to work in close association with the MreB-based
48 Rod complex (*Pazos et al., 2017*), motivated by biochemical interactions between PBP1a and the
49 Rod-complex TPase PBP2 (*Banzhaf et al., 2012*), and by similar interactions between PBP1b and the
50 divisome TPase PBP3 (*Bertsche et al., 2006*). However, each set of enzymes remains active upon
51 inhibition of the respective other one and aPBPs and Rod-complex components show different
52 sub-cellular motion (*Cho et al., 2016*). Furthermore, cells inhibited in PBP1ab activity rapidly lyse
53 (*García del Portillo et al., 1989; Wientjes and Nanninga, 1991*), while cells inhibited in Rod-complex
54 activity become round but don't lyse (*Lee et al., 2014*).

55 Since aPBPs and Lpo's form envelope-spanning complexes (*Egan et al., 2014; Jean et al., 2014*)
56 they have been suggested to work as repair enzymes that activate at site of defects or large
57 pores in the peptidoglycan (*Typas et al., 2012; Cho et al., 2016*). In support of this idea, aPBP
58 activity was increased (*Lai et al., 2017*) upon over-expression of the DD-endopeptidase MepS, which
59 cleaves peptide bonds (*Singh et al., 2012*). Therefore, Rod complex and aPBPs might serve different
60 functions despite catalyzing the same chemical reactions (*Zhao et al., 2017; Pazos et al., 2017*). In
61 agreement with this viewpoint, recent work in the gram-positive *Bacillus subtilis* showed that the two
62 machineries have opposing actions on cell diameter and lead to either circumferentially organized
63 or disordered cell-wall deposition (*Dion et al., 2019*).

64 Based on the selective interactions between PBP1a-PBP2 and PBP1b-PBP3 (*Banzhaf et al., 2012;*
65 *Bertsche et al., 2006*), and based on a mild localization of PBP1b at the cell septum (*Bertsche*
66 *et al., 2006*), PBP1a was suggested to be mostly involved in cell elongation and PBP1b in cell
67 division. However, PBP1b also contributes to cell elongation, where it might have an even more
68 important role than PBP1a under normal growth conditions: PBP1b localizes throughout the cell
69 envelope, with only a mild enrichment at the septum (*Bertsche et al., 2006; Paradis-Bleau et al.,*
70 *2010*). Furthermore, strains lacking PBP1b have greater mechanical plasticity in the cylindrical part
71 of the cell (*Auer et al., 2016*), their overall rate of peptidoglycan insertion is reduced (*Caparrós et al.,*
72 *1994*), they are more sensitive to chemicals targeting side-wall elongation, including mecillinam
73 (*García del Portillo and de Pedro, 1991*), A22 (*Nichols et al., 2011*), and D-methionine (*Caparrós*
74 *et al., 1992*), and they cannot recover from spheroplasts (*Ranjit et al., 2017*).

75 Here, we study the role of aPBPs for cell shape and cell-wall integrity. First, we measure viability
76 and cell shape during steady-state growth at different protein levels. We found that aPBPs have
77 no role in maintaining cell shape and are therefore not required for proper Rod-complex activity.
78 On the contrary, we confirmed that aPBPs are essential for mechanical cell-wall integrity. Second,
79 we investigate how the major aPBP PBP1b contributes to mechanical integrity: simply through a
80 higher overall rate of peptidoglycan insertion (*Caparrós et al., 1994*), by constitutively stabilizing
81 cell-wall, for example by inserting peptidoglycan in a more spatially homogeneous manner, or
82 through active repair of local cell-wall damage, as previously suggested (*Typas et al., 2012; Lai et al.,*
83 *2017; Cho et al., 2016*). We first measured mechanical stability and rate of peptidoglycan insertion
84 in cells with aPBP levels reduced three-fold. These cells showed reduced cell-wall stiffness and
85 integrity while maintaining a high rate of peptidoglycan insertion. Therefore, PBP1b apparently
86 strengthens the cell wall independently of changes in insertion rate. Increased integrity could then
87 come about either through constitutive PBP1b activity or through an adaptive repair mechanism
88 (*Typas et al., 2012*). Using a combination of cell-wall perturbations and time-dependent expression
89 of PBP1b, we found that PBP1b facilitates cell survival as quickly as 5 min after protein expression,
90 suggesting that PBP1b senses and repairs cell-wall defects. As a complementary approach, we
91 used single-molecule tracking of a GFP-PBP1b fusion. We found that the bound, non-diffusive




Figure 1. aPBPs have no role in maintaining rod-like cell shape.

A: Sketch of the strain AV44 (LC69 *mrcB::gfp-mrcB*, *mrcA::rfp-mrcA*) with tunable levels of PBP1a and PBP1b. CRISPR guides are expressed either as crRNA (top) or as sgRNA (bottom), see also Figure 1 - Supplement 1.

B: Doubling time of AV51 (AV44 Δ PBP1a)/pAV20 as a function of PBP1b level, in minimal medium with glucose and casamino acids at 30°C. sgRNA are expressed from pAV20 as annotated. AV58 is AV51 P_{Bad} -GFP-PBP1b for over-expression. Skull logo: not viable.

C: Effect of aPBP concentration on cell diameter. Points indicate the median diameter within each population. Green: AV51/pCRRNacos with crRNA G20, G14, G10 and GØ, or AV58 (over-expression). Red: AV50 (AV44 Δ PBP1b)/pCRRNacos with crRNA R20, R18, R11 and RØ. AV63 is AV50 HK022:: P_{Bad} -RFP-PBP1a for over-expression. Levels were determined based on fluorescence and normalized with respect to WT according to DIA.

D: Effect of the concentration of Rod-complex proteins on cell diameter. Green: AV88 (LC69 MreB-*msfGFP*)/pAV20 with sgRNA G14, G10 or GØ. Red: AV08 (LC69 RFP-PBP2)/pAV20 with crRNA G20, G14, G10 or GØ.

E: Growth curve of AV44/pAV20 with PBP1ab repressed to lethal level (sgRNA G20-R20), and cell morphology during lysis. Individual points are biological replicates. OD: optical density. WT: wild-type.

92 fraction of PBP1b molecules decreased with increasing PBP1b or PBP1a levels and increased with
 93 LpoB levels, suggesting that PBP1b binds to regions of the cell wall in a need-based manner,
 94 which is facilitated through LpoB. Second, we effectively increased the average cell-wall pore size
 95 by transiently inhibiting cell-wall insertion during growth. We found that the bound fraction of
 96 PBP1b molecules increased shortly after drug treatment and remained high up to 20 min after
 97 washout, supporting that PBP1b molecules directly respond to cell-wall damage. Together, our
 98 results demonstrate that PBP1b is responsible to maintain the integrity and structural organization
 99 of peptidoglycan on a local scale by actively repairing cell-wall defects, while neither of the two
 100 aPBPs has a role in cell-shape maintenance.

101 Results

102 Class-A PBPs are dispensable for cell shape but required for cell-envelope integrity

103 To investigate the importance of aPBPs for cell shape and cell-wall integrity, we constructed a
 104 strain with tunable levels of PBP1a and 1b using partial CRISPR knock-down, which reduces the
 105 transcription rate by a fractional amount (Vigouroux et al., 2018). To that end, we used the strain
 106 LC69 (P_{Tet} -dCas9) (Cui et al., 2018) and fused PBP1a and PBP1b to RFP (mCherry) and GFP (sfGFP) in
 107 their native loci, respectively (strain AV44). We then used combinations of different CRISPR guides

108 targeting GFP and RFP with a variable number of mismatches (*Vigouroux et al., 2018*). To extend
109 the range of possible repression levels, CRISPR guides were expressed in two different forms: i)
110 as a CRISPR RNA (crRNA) co-expressed with the tracrRNA, on the pCRRNacos vector (*Vigouroux*
111 *et al., 2018*) or ii) as a single-guide (sgRNA) with fused crRNA and tracrRNA, on the pAV20 vector
112 (*Dion et al., 2019*) (Figure 1A). The CRISPR guides are named according to their complementarity
113 to GFP (G) or RFP (R), \emptyset designating a control guide. Increasing complementary leads to increased
114 repression (Figure 1 - Supplement 1 and table 8).

115 To ensure that no truncated or non-fluorescent form of PBP1a or PBP1b was produced, we
116 used bocillin-labeled SDS-page (Figure 1 - Supplement 2A). We quantified PBP1ab protein levels
117 by combining relative mass spectrometry (Data-Independent Acquisition or DIA), absolute mass
118 spectrometry (Parallel Reaction Monitoring or PRM), SDS-page and single-cell fluorescence mea-
119 surements (see methods and table 1).

120 The absolute number of PBP1b per cell in the WT is 166 ± 26 , in agreement with previous
121 measurements (*Dougherty et al., 1996*). However, levels of non-repressed RFP-PBP1a and GFP-
122 PBP1b were 1300% and 370% higher than their homologs in the wild-type (table 1), reminiscent
123 of previous reports of elevated levels for fluorescent fusions (*Paradis-Bleau et al., 2010*). While
124 not anticipated, this allowed us to explore aPBP levels ranging from strong repression to strong
125 over-expression.

126 Interestingly, when repressing GFP-PBP1b, the residual expression was higher than the what the
127 same CRISPR guides would produce on constitutive GFP (Figure 1 - Supplement 4, left), suggesting
128 that a form of negative feedback raises PBP1b expression in response to repression. We did not
129 detect such a feedback for RFP-PBP1a (Figure 1 - Supplement 4, right).

130 As expected from the synthetic lethality of PBP1ab, strains with a strong repression of both
131 PBP1a and PBP1b did not survive. In particular, in strain AV51 (Δ PBP1a), repressing PBP1b to about
132 4% of WT level using the perfect-match sgRNA G20 (fluorescence microscopy, table 1) leads to cell
133 death. In contrast, AV51 with PBP1b repressed to 30% (DIA, table 1) with sgRNA G14 is still viable.
134 For all the strains which survived repression, the growth rate was unaffected, regardless of aPBPs
135 levels (Figure 1B).

136 To systematically measure the impact of PBP1ab levels on cell morphology, we varied the level
137 of each PBP between 30 and 1300% (DIA) in strains lacking the respective other PBP. Expression
138 had hardly any effect on cell shape (Figure 1C). From lowest to highest PBP1a or PBP1b levels cell
139 diameter increased by only 75 nm. In contrast, a 10-fold decrease in the level of Rod-complex-related
140 operons PBP2-RodA or MreBCD increased diameter by about 800 nm (Figure 1D), as previously
141 demonstrated (*Vigouroux et al., 2018*). Our observations are also in stark contrast to *B. subtilis*,
142 where a similar change of the level of the major class A PBP PBP1 leads to a 600 nm increase in
143 diameter (*Dion et al., 2019*). As a control, we used an alternative setup based on the inducible P_{Bad}
144 promoter (strains AV100, AV101) and checked the lack of major shape phenotype at low PBP1ab
145 induction (Figure 1 - Supplement 2BC).

146 We also examined the shape of cells that were depleted for PBP1ab to the point of lysis. To
147 that end we used time-lapse microscopy after induction of our strongest sgRNAs (20 bp of com-
148 plementarity for each target, see table 1). Cells abruptly lysed without changes in cell dimensions
149 compared to the minimum viable expression level (Figures 1E and 1 - Supplement 5). However, we
150 often observed small bulges on the sides of the cells just before lysis. This behavior, previously also
151 observed upon LpoAB depletion (*Typas et al., 2010*), is similar to the effect of beta-lactam antibi-
152 otics (*Chung et al., 2009*), suggesting that cells accumulate lethal cell-wall defects in the absence of
153 PBP1ab.

154 Together, our observations suggest that aPBPs are required for cell-wall integrity at the local
155 scale but dispensable for the maintenance of rod-like cell shape.

156 **At low levels of aPBPs, cells insert as much peptidoglycan as WT but show reduced**
157 **mechanical integrity**

158 Next, we aimed to study whether aPBPs maintain cell-wall integrity simply due to an elevated rate
159 of cell-wall insertion or by modulating the cell wall structurally, e.g., through a more homogeneous
160 distribution of peptidoglycan material (*Typas et al., 2012*). It was previously reported that a Δ PBP1b
161 strain inserts about 50% less peptidoglycan, while a Δ PBP1a strain maintains a WT insertion rate
162 (*Caparrós et al., 1994*). We therefore reasoned that the rate of peptidoglycan insertion might not
163 depend on aPBP abundance, as long as a minimum level of PBP1b was present. To study this
164 possibility, we measured the rate of peptidoglycan insertion by recording the incorporation of the
165 radio-labeled cell-wall precursor mDAP (meso-diaminopimelic acid) (*Wientjes et al., 1991*) (Figure 2
166 - Supplement 1). In AV105 (AV44 Δ PBP1b Δ LysA), peptidoglycan insertion was reduced to about 2/3,
167 even with a high level of PBP1a (Cohen's $d=4.16$, $p=0.014$, t-test, Figure 2A). When repressing PBP1b
168 strongly in AV84 (AV44 Δ LysA) with sgRNA G20, leading to a residual expression of about 4% (table
169 1), we measured a similar reduction of peptidoglycan insertion as in Δ PBP1b. Intriguingly, when
170 we reduced both PBP1a and PBP1b to about 30% of WT using sgRNA G14-R20 in AV84, the cells
171 inserted
172 PBP1b (Cohen's $d=0.56$, $p=0.53$, t-test, Figure 2A). Therefore, the rate of peptidoglycan insertion is
173 independent of PBP1ab levels as long as PBP1b is expressed at a minimum level between 5-30% of
174 native levels. Furthermore, the decrease of peptidoglycan insertion upon strong PBP1b repression
175 or deletion cannot be compensated by high PBP1a expression, since a strain with 20% of PBP1a
176 and 30% of PBP1b (AV84/pAV20 G14-R20) still inserts more peptidoglycan than a strain with 1300%
177 PBP1a but no PBP1b (AV105/pAV20 GØ-RØ) (Cohen's $d=4.38$, $p=0.016$).

178 We also measured the chemical composition of the cell wall in these strains through HPLC-UV.
179 No large difference was observed in any of the peaks, meaning that the rate of cross-linking is
180 not affected by the repression (Figure 1 - Supplement 6B), in contrast to what was observed *in*
181 *vitro* (*Mueller et al., 2019*). Together, these data confirm that peptidoglycan insertion by aPBPs
182 is rigorously buffered against variation in their levels, and buffering holds over a wide range of
183 concentrations.

184 Next, we wondered whether the reduction of PBP1ab to low levels might have any effect on the
185 mechanical integrity of the cell wall, even if the rate of peptidoglycan insertion remained high and
186 the composition was unaffected. Previously, it has been reported that cells lacking PBP1b have a
187 more elastic cell wall (*Auer et al., 2016*), a measure of mechanical integrity. To measure potential
188 changes of cell-wall elasticity, we submitted the strain to an osmotic downshock of 1 osm/L of NaCl
189 under the microscope, similarly to (*Buda et al., 2016*) (Fig. 2B and C). To avoid rapid response to
190 osmotic shock, we deleted the mechano-sensitive channels *mscS* and *mscL* from AV44 (strain AV93).
191 The sudden increase of turgor pressure causes an increase of cell dimensions that is inversely
192 related to cell-wall stiffness, in agreement with (*Buda et al., 2016*). We found that repression of
193 PBP1ab to about 30% of WT levels (in AV93/pAV20 G14-R20) leads to a decrease of both axial and
194 circumferential stiffness if compared to the non-repressed strain (Figure 2B and C). Therefore, the
195 reduced number of PBP1ab is likely less capable to protect the cell wall against the accumulation of
196 mechanical defects, despite unperturbed peptidoglycan density and chemical composition.

197 As a potential consequence of reduced mechanical integrity, we next studied cell survival after
198 osmotic shock in batch culture (Figure 2D and 2 - Supplement 2). In AV93/pAV20, the osmotic
199 shock caused death of a large fraction of cells repressed for PBP1ab (sgRNA G14-R20), while the
200 non-repressed cultures (sgRNA GØ-RØ) were mostly unperturbed.

201 In summary, we found that cells with reduced levels of PBP1ab showed reduced mechanical
202 stiffness and integrity, which led to an increased rate of cell death upon osmotic downshock, despite
203 unperturbed levels of peptidoglycan density and chemical composition. Therefore, the lack of
204 PBP1ab perturbs cell-wall structure independently of peptidoglycan density.




Figure 2. Repression of PBP1ab reduces mechanical stiffness while maintaining a high rate of peptidoglycan insertion. **A:** Rate of insertion of ^3H -mDAP into the cell wall measured in AV84 (AV44 Δ lysA)/pAV20 and AV105 (AV44 Δ mrcB Δ lysA) as annotated. NS: not significant. **B-C:** Extension of the cells' long axis (B) and short axis (C) after a 1 osm/L NaCl downshock, in AV93 (AV44 Δ mrcLS)/pAV20 with sgRNA G0-R0 or G14-R20. A value of one corresponds to no extension. **D:** Growth curves before and after a 1 osm/L osmotic downshock, in AV93/pAV20 with sgRNA G0-R0 or G14-R20. OD: optical density.

205 PBP1b actively repairs cell-wall damage

206 PBP1ab could in principle increase mechanical integrity in two different ways: through constitutive
 207 peptidoglycan synthesis that compensates the accumulation of mechanical defects but does not
 208 respond to the presence of existing defects, or through an active repair mechanism that inserts
 209 cell wall in response to damage, as previously proposed (Typas et al., 2012). To discriminate these
 210 two possibilities, we studied the ability of PBP1b to sustain and recover from transient inhibition of
 211 peptidoglycan insertion. Specifically, we blocked peptidoglycan-precursors production by treating
 212 cells with the antibiotic D-cycloserine, which inhibits L-alanine to D-alanine conversion and D-
 213 alanine-D-alanine ligation (Lambert and Neuhaus, 1972), or by starving an auxotrophic mutant
 214 strain (*asd-1*) for the essential peptidoglycan component mDAP (Hatfield et al., 1969). Different
 215 from the above experiments, we expressed PBP1b from a multi-copy plasmid (pBC03) under the
 216 control of an inducible P_{Bad} promoter in a Δ PBP1b background for rapid and wide modulation of
 217 PBP1b levels. The condition where PBP1b expression is induced will be referred as PBP1b+ and
 218 PBP1b- otherwise.

219 Upon treatment with a high concentration of D-cycloserine (1 mM) under the microscope, cells
 220 continued to elongate at a nearly unperturbed rate for about 20-30 minutes before they suddenly
 221 lysed (Figure 3A). In batch experiments, WT cells, PBP1b+ cells and PBP1b- cells lysed almost at the
 222 same time on average (Figure 3B), demonstrating that the structure of the cell wall prior to drug
 223 treatment and the presence of PBP1b during drug treatment have no impact on cell survival.

224 Notably, cell-wall synthesis was affected well before lysis according to the rotational motion
 225 of a fluorescent-protein fusion to MreB (MreB-msfGFP) (Ouzounov et al., 2016), which, in turn,
 226 requires cell-wall insertion (Teффelen et al., 2011). Within 15 min after drug treatment, processive

227 rotation of MreB-msfGFP stalled (Figure 3 - Supplement 1A), suggesting that cell-wall synthesis
228 was severely reduced at this time. Thus, we reasoned that the density of the cell wall decreased
229 during precursors depletion, as the cells continue to elongate while inserting material at a severely
230 reduced rate.

231 To study the potential role of PBP1b for cell-wall repair, we washed out D-cycloserine after 25
232 min of treatment, right before rapid lysis would have started, and monitored growth (Figure 3C).
233 We found that PBP1b- cells showed extensive lysis after drug removal while almost all PBP1b+
234 cells recovered from damage. To discriminate whether the elevated rate of recovery was due to
235 increased mechanical integrity prior to drug treatment or due to PBP1b activity after washout we
236 compared PBP1b- cells with cells that expressed PBP1b only right before washout. We found that
237 these cells recovered nearly as well as cells expressing PBP1b during the whole experiment. The
238 alleviating effect of PBP1b was almost immediate (<5 min after drug removal). The rapid effect on
239 cell survival suggests that PBP1b actively responds to cell-wall damage and repairs defects.

240 We observed similar but slightly different behavior upon mDAP depletion and re-addition of
241 mDAP in an mDAP auxotroph (Figure 3D,E). Different from D-cycloserine, mDAP depletion induced
242 lysis only after about 60 min on average in PBP1b+ cells, suggesting that cell-wall synthesis was
243 inhibited later than during D-cycloserine treatment. This is in agreement with previous experiments
244 (*Teeffelen et al., 2011*), where some of us observed a slow reduction of MreB rotation, when cells
245 were grown in minimal medium. Surprisingly, here we observed that MreB-msfGFP rotation was
246 severely reduced within 10-20 min (Figure 3 - Supplement 1C), a similar time as after D-cycloserine
247 treatment. Possibly, a low, non-detected level of cell-wall synthesis was still ongoing.

248 In contrast to PBP1b+ cells, PBP1b- cells already lysed after about 35 min on average (Figure 3D).
249 We therefore reasoned that PBP1b repaired damage both during and after mDAP depletion.

250 After re-addition of mDAP following 35 min of mDAP depletion we found that expressing PBP1b
251 right before mDAP repletion had an immediate effect on survival (Figure 3E). However, expressing
252 PBP1b during the whole experiment led to an even faster recovery, presumably because PBP1b
253 helped maintain cell-wall integrity during the 35 min of mDAP depletion.

254 At a sub-lethal concentrations of D-cycloserine (100 μ M), Δ PBP1b cells lysed after about 60 min,
255 while the WT continued to grow, as reported previously (*Nichols et al., 2011*) (Figure 3 - Supplement
256 2). Similarly to the mDAP depletion experiment, PBP1b+ cells presumably have the capacity to use
257 the reduced pool of peptidoglycan precursors to counter the accumulation of mechanical defects.
258 Together, our findings demonstrate that PBP1b responds to cell-wall damage in an active manner
259 and repairs cell-wall defects.

260 **PBP1b localizes in response to cell-wall defects**

261 To investigate the active response of PBP1b to cell-wall damage at the molecular level, we studied the
262 movement of individual GFP-PBP1b molecules in the inner membrane. Different from Figure 3, we
263 used minimal medium supplemented with glucose and casamino acids to reduce autofluorescence.

264 Previously, single-molecule tracking of PBP1a in *E. coli* (*Lee et al., 2016*) and PBP1 in *B. subtilis*
265 (*Cho et al., 2016*) revealed that enzymes can be divided in two populations: a diffusive fraction
266 and a "bound" fraction with near-zero diffusion coefficient. Presumably, only the bound fraction
267 can insert peptidoglycan, while the diffusive fraction is searching for new insertion sites. Notably,
268 bound molecules were detected for a duration of at most a few seconds, which did not allow to
269 identify any persistent motion expected from processive transglycosylation.

270 To localize individual GFP-PBP1b molecules, we first bleached a large fraction of all molecules
271 in HILO (highly inclined and laminated optical sheet) or epifluorescence mode and then tracked
272 single GFP-PBP1b molecules with an imaging interval of 60 ms in HILO or Total Internal Reflection
273 Fluorescence (TIRF) mode. The fraction of bound molecules was measured by fitting the observed
274 distributions of single-molecule displacements to a two-state model using the Spot-On tool
275 (*Hansen et al., 2018*) (Figure 4 - Supplement 1). The fit-parameter values for all conditions are
276 indicated in table 3.




Figure 3. PBP1b facilitates fast recovery from transient inhibition of peptidoglycan synthesis.

A: Increase of cell length during D-cycloserine treatment (1 mM) under the microscope, with sample snapshots. Strain is AV51 (AV44 Δ PBP1a). Length is normalized by the length at the beginning of the movie. Solid lines describe growing cells, dashed lines correspond to phase-bright, lysing cells. Colors are arbitrary. **B:** Treatment with 1 mM D-cycloserine. Comparison of MG1655 (WT) and B150 (Δ PBP1b)/pBC03 (pBAD33- P_{Ara} PBP1b) with arabinose (overexp.) or without arabinose (non-induced). **C:** Recovery of B150/pBC03 after drug washout following 25 min of D-cycloserine treatment (1 mM). PBP1b is either always induced, never induced, or induced 5 min before recovery. **D:** mDAP depletion in the mDAP auxotroph B151 (FB83 *asd-1* (Teeffelen et al., 2011)) for WT or B157 (F83 Δ PBP1b *asd-1*)/pBC03 for non-induced/overexp. PBP1b is expressed at different levels like in (C). **E:** Recovery of B157 (F83 Δ PBP1b *asd-1*)/pBC03 after 35 min of mDAP depletion. PBP1b is either always induced, never induced, or induced 5 min before recovery. Shaded areas correspond to mean \pm standard deviation of 3 biological replicates. Growth measurements are performed in shaking flasks (B) or microplate reader (C-E). WT: wild-type. OD: optical density.

277 In order to approximate WT levels in our fluorescently-labeled strain, we used the crRNAs G10
 278 and R18, leading to an expression of 130% for GFP-PBP1b and 280% for RFP-PBP1a (table 1). Using
 279 a Δ PBP1a background (AV51) we found about 20% of the PBP1b molecules to be bound around WT
 280 levels (crRNA G10), while 80% of the molecules moved diffusively with a diffusion constant of about
 281 $0.075 \mu\text{m}^2/\text{s}$. Here, bound molecules were found all along the cell axis (and not only at mid-cell)
 282 (Figure 4 - Supplement 2).

283 Qualitatively similar to the observations on the major aPBP PBP1 in *B. subtilis* (Cho et al., 2016),
 284 we found that the bound fraction of PBP1b decreased with increasing concentration (Figure 4A),
 285 suggesting that the activity of individual PBP1b enzymes is reduced upon increasing levels.

286 The activity of individual PBP1b molecules could be limited by the availability of LpoB molecules,
 287 the availability of peptidoglycan precursors, or the abundance of potential sites for cell-wall insertion,
 288 henceforth referred to as defects. We therefore aimed to identify the potentially limiting factors
 289 by modulating protein levels and precursor availability. First, we modulated LpoB levels. Over-
 290 expressing LpoB from plasmid pBC01 (pAM238- P_{Lac} -*lpoB*) in AV44/pAV20 G10-R18 indeed increased
 291 the bound fraction, while deleting LpoB (strain AV110/pAV20 G10-R18) reduced the bound fraction
 292 (Figure 4B), indicating that the physical interaction with LpoB aids PBP1b immobilization or stabilizes
 293 the bound form.

294 Next, we investigated how the fraction of bound PBP1b molecules responded to changes of
 295 PBP1a abundance. Maintaining PBP1b at about 30% of WT, we found that the bound fraction
 296 of PBP1b was reduced about 4-fold upon over-expression of PBP1a (1300% with respect to WT),
 297 compared to the Δ PBP1a background (Figure 4C). We reasoned that PBP1a affects PBP1b indirectly
 298 through its enzymatic activity, since PBP1a and PBP1b do not share their outer-membrane activators
 299 LpoA and LpoB (*Typas et al., 2010*). This could happen through depletion of the common precursor
 300 pool or by reducing the number of cell-wall defects detected by PBP1b-LpoB pairs.




Figure 4. PBP1b localizes depending on the need for peptidoglycan synthesis. A-D: Calculated bound fraction of PBP1b at different levels of PBP1b, PBP1a and LpoB, using strains AV44, AV51 (Δ PBP1a) or AV110 (Δ LpoB). For GFP-PBP1b, sgRNA G14 (from pAV20), crRNA G10 (from pCRRNAcos) and crRNA G \emptyset (from pCRRNAcos) are used to reach 30%, 130% and 370% respectively. For RFP-PBP1a, sgRNA R20 (from pAV20), crRNA R18 (from pCRRNAcos) and crRNA R \emptyset (from pCRRNAcos) are used to reach 20%, 278% and 1300% respectively. LpoB is over-expressed using pBC01 (pAM238- P_{Lac} -*lpoB*), compared to an empty pAM238 vector, so all cells are grown in the same conditions, in the strain AV44/pCRRNAcos G10-R18. Each point represent a biological replicate comprising at least 5000 tracks. Horizontal lines are means. **D-E:** Bound fraction of PBP1b-sfGFP at different times during D-cycloserine treatment (E) and during recovery from 30 min of D-cycloserine treatment (F) in the strain AV51/pCRRNAcos G10-R \emptyset . Colored points are individual movies and white points are medians for each culture. Corresponding free diffusion coefficients are shown in figure 4 - Supplement 4.

301 To test whether PBP1b immobilization happened immediately after changes of the cell-wall
 302 architecture, we transiently inhibited precursor synthesis using D-cycloserine as in figure 3. First,
 303 we confirmed that D-cycloserine had the same qualitative effect as in LB (cf. Figure 4 - Supplement
 304 3): Cells lysed after 30-60 min (Figure 4 - Supplement 3A,B), while cell-wall insertion was severely
 305 reduced within 10-20 min according to MreB motion (Figure 4 - Supplement 3C,D).

306 Using single-molecule tracking, we observed a rise of the bound fraction of PBP1b within less
 307 than 20 min and a subsequent increase to 37% within 40 min (Figure 4E), while the diffusion
 308 constant of diffusive PBP1b molecules was only mildly reduced (Figure 4 - Supplement 4). To make

309 sure that the increase of the bound fraction was due to live, non-lysed cells, we investigated cell
310 shape and also used the nucleic-acid dye propidium iodide, which only penetrates the membranes
311 of dead cells. We then confirmed that visibly dead cells only contributed a small number of tracks
312 to our dataset. Furthermore, while the number of lysed cells visibly rose during the latest set of
313 of movies corresponding to Figure 4 - Supplement 4D (from about 5 to 20% according to visual
314 inspection), we did not observe a concurrent increase of the bound fraction. Our experiments
315 therefore suggest that PBP1b molecules immediately respond to damage by increased binding.
316 Furthermore, the prior arrest of MreB motion suggests that PBP1b binding does not require PBP1b
317 activity or precursor availability.

318 We then also investigated whether PBP1b showed a higher bound fraction during recovery from
319 D-cycloserine, where the presence of PBP1b greatly increases the chance of cell survival (Figure 3C).
320 In agreement with our expectation, we found that the bound fraction was elevated for about 20 min
321 after a 30 min period of D-cycloserine treatment (Figure 4F).

322 In summary, our tracking results are compatible with our conclusion above, that PBP1b to-
323 gether with its cognate activator LpoB contributes to cell-wall integrity by localizing and inserting
324 peptidoglycan in response to local cell-wall defects.

325 Discussion

326 In conclusion, we found that different cell-wall-synthesizing machineries have distinct functions in
327 *E. coli*. While the Rod complex is essential for rod shape, the bifunctional aPBPs PBP1ab have hardly
328 any effect on cell shape, up to the point of cell lysis. However, PBP1ab are essential for mechanical
329 cell-wall integrity, and we could demonstrate that PBP1b inserts peptidoglycan in response to local
330 cell-wall defects. Our work therefore contributes to a growing body of evidence suggesting that the
331 local mechanical and structural state of the cell wall provides a major physical cue for peptidoglycan
332 remodeling and insertion.

333 While cell shape was hardly affected by PBP1ab repression, we found a mild but significant
334 positive correlation between cell diameter PBP1ab levels, consistent with a previous study of a
335 Δ PBP1a mutant (Banzhaf *et al.*, 2012). A much stronger correlation between a class-A PBP levels
336 and cell diameter of same sign was recently also observed in *B. subtilis* (Dion *et al.*, 2019). In both
337 species, it is conceivable that increased aPBP activity depletes a common pool of lipid II precursors
338 and thus indirectly reduces the capacity of the Rod complex to maintain a narrower cell diameter.
339 What then is responsible for the qualitatively different effect of aPBP levels on cell diameter in
340 *E. coli* and *B. subtilis*? First, our tracking experiments showed that the bound fraction of PBP1b
341 molecules was negatively correlated with PBP1ab expression and positively correlated with LpoB
342 levels. These findings support the model that PBP1b activity is controlled by both the structure of
343 the cell-wall substrate and by the presence of LpoB. In *B. subtilis*, cell-wall synthetic activity of PBP1
344 might be less regulated, even if PBP1 molecules are less immobile at high expression level (Cho
345 *et al.*, 2016). Second, the flux of lipid-II precursors shared by both systems might not be fixed in
346 *E. coli*. Instead, both systems might secure access somewhat independently, as also supported by
347 the overall increase in peptidoglycan synthesis upon MepS over-expression (Lai *et al.*, 2017). Finally,
348 LpoB might play an important limiting factor for PBP1b activity, which is absent in *B. subtilis*.

349 At first sight, our observation of an increasing PBP1b bound fraction with decreasing PBP1a
350 levels seems to be in contradiction to previous measurements of PBP1b diffusion Lee *et al.* (2016).
351 Lee *et al.* reported that deletions of either LpoB or PBP1a hardly affected the average diffusion
352 constant of PBP1b molecules. Similar to our approach, they fused PBP1b to a fluorescent protein
353 (PAmCherry) in the native chromosomal locus. Therefore, it is possible that PBP1b expression was
354 also elevated in their strain, similar to our GFP-PBP1b fusion. We found that at high levels the
355 bound fraction of PBP1b is low, even in the absence of PBP1a (Figure 4A). Expressing PBP1a might
356 then only elicit a small relative change of the PBP1b bound fraction that is hard to detect in the
357 average diffusion constant.

358 Consistently with average diffusion constants reported in *Lee et al. (2016)* we found that the
359 bound fraction of PBP1b was only mildly reduced upon LpoB deletion, even if both PBP1ab were
360 expressed at native levels. This observation demonstrates that PBP1b does not strictly require
361 LpoB for binding. We reasoned that PBP1b might be able to autonomously detect defects or
362 sites for cell-wall insertion in the absence of LpoB. This hypothesis is consistent with the previous
363 identification of a PBP1b mutant that suppresses the lethality of a Δ PBP1a Δ LpoB background
364 (*Markovski et al., 2016*) and with the high residual activity of PBP1b in the absence of LpoB *in vitro*
365 (*Paradis-Bleau et al., 2010*). Alternatively, PBP1b molecules might associate with one or multiple
366 different proteins that immobilizes independently of LpoB. For example, it has been suggested
367 that aPBPs interact with hydrolytic enzymes and with an outer-membrane bound nucleator of
368 cell-wall hydrolases (*Banzhaf et al., 2019*). As another possibility, a fraction of PBP1b molecules
369 might co-localize with the Rod complex or the divisome. We have recently shown that Rod-complex
370 activity remains surprisingly high upon RodA depletion (*Wollrab et al., 2019*) and we reasoned that
371 a different transglycosylase might compensate for the absence of RodA. It will thus be interesting
372 to study the possibility of PBP1b or PBP1a to rescue Rod-complex activity in the absence of RodA in
373 the future.

374 While repair enzymes are well understood in the context of DNA damage, PBP1b is the first
375 enzyme demonstrated to be involved in the repair of the peptidoglycan cell wall. Yet, the cell wall
376 experiences nearly constant damage due to cell-wall expansion during growth or due to the action of
377 cell-wall antibiotics, making repair all the more important. Recent work by some of us demonstrates
378 that cell-wall cleavage likely happens in regions of elevated mechanical strain and stress (*Wong*
379 *et al., 2017*). In the absence of repair, increased hydrolytic activity in regions of increased strain
380 would then rapidly lead to more strain and eventually to lysis, as also predicted by computational
381 simulations (*Furchtgott et al., 2011*) and as observed upon depletion of PBP1ab (Figure 1E) or upon
382 treatment with peptidoglycan-synthesis inhibitors (*Yao et al., 2012*). We therefore think that more
383 enzymes might insert peptidoglycan in a manner dependent on the local structure of the cell wall.
384 Consistently, we recently demonstrated that the Rod complex initiates at locations determined
385 by the transpeptidase PBP2, which likely binds to the cell wall directly, in a cell-wall-architecture-
386 dependent manner (*Wollrab et al., 2019*). In the future, the challenge remains to identify the
387 particular local features of the cell wall that attract different cell-wall-modifying enzymes.

388 Experimental procedures

389 Growth conditions

390 Cloning and strain preparation were done in Luria-Bertani (LB) medium. Unless mentioned other-
391 wise, every measurement was done in the same M63 with 0.2% glucose, 0.1% casamino acids and
392 0.5% thiamine. For the experiments of inhibition of peptidoglycan synthesis, cells were grown in
393 LB medium supplemented with arabinose 2 mg/ml if indicated (see below) and mDAP auxotroph
394 strains were grown in LB supplemented with mDAP (50 μ g/ml) and L-homoserine (50 μ g/ml) from
395 Sigma-Aldrich. For experiments involving the P_{bad} promoter in minimal medium, we used 0.5%
396 lactose instead of glucose as a carbon source. For single-molecule tracking, the concentration
397 of casamino acids used during the preculture and in the agar pad was only 0.01% to minimize
398 background fluorescence.

399 As needed, media were supplemented with kanamycine (50 μ g/ml), carbenicillin (100 μ g/ml),
400 chloramphenicol (25 μ g/ml) or spectinomycin (50 μ g/ml), all from Sigma-Aldrich. CRISPR repression
401 is induced with 100 ng/ml of anhydro-tetracycline (Acros Organics). For over-expression of PBP1a
402 or PBP1b from P_{Bad} , 2 mg/ml of arabinose (Sigma-Aldrich) were added to the medium. For over-
403 expression of LpoB or MepS from P_{Lac} , we added 1 mM of IPTG. The concentration of propidium
404 iodide used to reveal dead cells was 0.4 μ M.

405 Whenever CRISPR knock-down was employed, dCas9 was induced over night so the repressed
406 gene had time to be diluted to steady-state levels. In the morning, the culture was back-diluted

407 1/500 and grown for at least 3h to ensure exponential growth before any experiment. Biological
408 replicates result from independent cultures grown from separate colonies.

409 **Genetic constructions**

410 All strains used in this study derive from the MG1655 and are described in table 4. Plasmids are
411 described in table 5. Gene deletions were carried out starting from the Keio collection (*Baba et al.*,
412 **2006**). P1 phage lysate was prepared from the Keio deletion strain, then used to infect the recipient
413 strain and the cells were plated on kanamycine to select for transducers. After each phage P1
414 transduction, as well as all “clonetegrations”, the kanamycine resistance marker was removed with
415 the flippase-expressing pE-FLP (*St-Pierre et al.*, **2013**). Integration of RFP-PBP1a and GFP-PBP1b
416 in the native locus was done using the allelic exchange procedure described in (*Vigouroux et al.*,
417 **2018**).

418 The plasmids constructed for this study were assembled by Gibson assembly, from the fragments
419 indicated in table 6. Oligonucleotide sequences can be found in table 7.

420 The CRISPR plasmids are either from the pcrRNA collection described in (*Vigouroux et al.*, **2018**),
421 or were assembled using the pAV20 double-sgRNA vector (*Dion et al.*, **2019**). In the later case,
422 complementary oligonucleotide pairs (table 8) were phosphorylated with T4 PNK in the presence
423 of T4 ligase buffer (New England Biolabs) and then annealed. A mix containing the pAV20 vector,
424 the two pairs of annealed oligos, the BsaI restriction enzyme (New England Biolabs), T4 ligase (New
425 England Biolabs) and ATP was subjected to thermal cycles for digestion, annealing and ligation.
426 The assembly product was subsequently electroporated in DH5 α and the resulting plasmids were
427 sequenced. The “ \emptyset ” control guides, producing no repression, still contain the same 5 bp seed
428 sequence as the sfGFP- and RFP-targeting guides. This is to account for potential mild “bad-seed
429 effect” (*Cui et al.*, **2018**).

430 **Measurement of optical density and doubling time**

431 Exponential cultures were then transferred to a flat-bottomed 96-microwell plate (Greiner) and
432 optical density at 600 nm was recorded during growth using a microplate reader (Tecan) or, if
433 indicated, using shaking flasks and a spectrophotometer (Eppendorf). To calculate the doubling
434 time, we fit an exponential function to the data points corresponding to the exponential phase.
435 To make sure that the exponential phase was properly isolated, we checked that there was no
436 correlation between consecutive residuals after the fit (Durbin-Watson statistic higher than 1).
437 Optical density at the peak was determined by calculating the first zero of the derivative of OD₆₀₀
438 after mean-filtering with a bandwidth of 10 min.

439 **Measurement of cell shape and fluorescence**

440 Cells were grown to steady-state exponential phase (OD₆₀₀ \approx 0.1) as detailed in ‘Growth conditions’
441 and fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 30 minutes, except for mea-
442 suring the fluorescence of cells repressed with sgRNA, which were fixed with 1 mg/ml kanamycine
443 in PBS for 30 min. Fixed cells were transferred to agarose pads (1.5% UltraPure Agarose; Invitrogen)
444 containing PBS and imaged using an inverted microscope (TI-E, Nikon Inc.) equipped with a 100 \times
445 phase-contrast objective (CFI PlanApo LambdaDM100 \times 1.4NA, Nikon Inc.), a solid-state light source
446 (Spectra X, Lumencor Inc.), a multiband dichroic (69002bs, Chroma Technology Corp.). GFP and
447 RFP fluorescence were measured using excitation filters (560/32 and 485/25 resp.) and emission
448 filters (632/60 and 535/50 resp.). Images were acquired using a sCMOS camera (Orca Flash 4.0,
449 Hamamatsu) with an effective pixel size of 65 nm. The Morphometrics package (*Ursell et al.*, **2017**)
450 was used to find cell contours from phase-contrast images. Cells that are in proximity from each
451 other were excluded using Morphometrics’ built-in algorithm. In addition, cells were filtered based
452 on their sharpness in phase-contrast (defined as the variance of gradient magnitude). Cell contours
453 were dilated by 1 pixel to capture all the fluorescence of proteins localized to the membrane. For
454 the analysis of fluorescence, we accounted for background intensity, uneven illumination, and cell

455 auto-fluorescence. Intracellular concentration was obtained by integrating the corrected fluores-
456 cence intensity inside cell contours, dividing by cell area and subtracting the background value for
457 the image. Total regression was used to find the major axis of the cell. The polar regions were
458 detected by setting a threshold on local contour curvature. Cell width was defined as the average
459 distance between the cell contour and this axis, excluding the poles. Cell length was calculated as
460 the maximal distance between contour points projected on the principal cell axis.

461 **Quantification of PBP1a and PBP1b**

462 The amount of PBP1a and PBP1b following repression by different CRISPR guides was quantified by
463 several methods.

464 First, we measured their expression in AV44 pAV20 GØ-RØ (non-repressed), AV44 pAV20 G14-R20
465 (strong repression) and LC69 (control strain without fusions) using mass spectrometry. We used
466 Data Independent Acquisitions (DIA) (*Bruderer et al., 2017*) for relative quantification of PBP1a
467 and PBP1b. We also used a targeted proteomics approach, Parallel Reaction Monitoring (PRM)
468 (*Bourmaud et al., 2016; Gallien et al., 2012; Peterson et al., 2012*), for absolute quantification
469 of PBP1b. We followed the same protocol previously described (*Wollrab et al., 2019*). Peptides
470 used for absolute quantification of PBP1b were based on the FASTA sequence obtained from
471 UniprotKB database and MS evidence of identification. Peptides sequences are LLEATQYR and
472 TVQGASTLTQQLVK (Aqua UltimateHeavy, Thermo Fisher Scientific).

473 As a confirmation, we used SDS-page with fluorescence detection to compare AV44 pAV20
474 GØ-RØ to AV44 pAV20 G14-R20. The detailed procedure is described as supplementary material.
475 Finally, for all the strains whose expression level was not quantified by SDS-page or DIA, we used
476 fluorescence microscopy to measure relative expression compared to non-repressed AV44, then
477 used the DIA measurement to obtain PBP1ab expression as a percentage of wild-type level. The
478 expression values obtained from the different methods are shown in table 1.

479 **mDAP incorporation measurement**

480 This experiment was done with the strains AV84 pAV20-GØ-RØ (non-repressed), AV84 pAV20-G14-
481 R20, AV84 pAV20-G20-RØ (Δ PBP1b) and AV105 pAV20-GØ-RØ (20-Ø) (see tables 4 and 8). These
482 strains are lacking *lysA* so radio-labeled mDAP is only used for cell wall synthesis.

483 Strains were grown to exponential phase and when OD₆₀₀ reached 0.4, ³H-labelled mDAP was
484 added for a final activity of 5 μ Ci/ml. For each time point, 200 μ l of culture were transferred to tubes
485 containing 800 μ l of boiling 5% SDS. After at least one hour of boiling, the samples were transferred
486 to 0.22 μ m GSWP filters. After applying vacuum, the filters were washed twice with 50 ml of hot
487 water. The filters were then moved to 5 ml scintillation vials, treated overnight with 400 μ l of
488 10 mg/ml lysozyme, and dissolved in 5 ml FilterCount cocktail (PerkinElmer) before counting.

489 The amount of ³H-mDAP per cell was calculated by dividing the total counts by the optical density
490 of the culture. The growth rate γ was obtained by fitting an exponential function to the OD₆₀₀ values
491 as a function of time. To calculate the incorporation rate k_{in} and turn-over rate k_{out} , we fit the data
492 with formula $\frac{{}^3\text{H-mDAP}}{\text{OD}_{600}} = \frac{k_{in}}{\gamma + k_{out}} (1 - e^{-t*(\gamma + k_{out})})$ with non-linear least squares optimisation. k_{out} is kept
493 constant across all cultures, assuming there are no difference in turn-over rate.

494 **HPLC content analysis of peptidoglycan**

495 Extraction of peptidoglycan from exponentially growing cells was done according to the protocol
496 described in *Wheeler et al. (2014)*. Chromatography of mutanolysin-digested peptidoglycan was
497 performed on a Shimadzu HPLC system with a hypersil Gold eQ 250x4.6 mm column with 3 μ m
498 particle size. The mobile phase was a 135 minutes-long gradient from water with 0.05% TFA to 50%
499 acetonitrile with 0.05%TFA. The flow was set to 0.5 ml/min.

500 **Measurement of cell elasticity and osmotic shock resistance**

501 Osmotic shifts were done by replacing a high-osmolarity medium (M63 with 1/10 volume 5 M NaCl)
502 with a low-osmolarity medium (M63 with 1/10 volume of water) for a shock magnitude of 1 osm. In
503 all cases, cells were grown overnight in high-osmolarity medium then diluted 1/500 and grown at
504 least 3h to reach exponential phase.

505 To perform osmotic shifts while monitoring cellular dimensions, we constructed a tunnel with
506 two strips of double-sided adhesive tape attached to a glass slide and a cover slip. Polylysine
507 was flushed in the tunnel then washed once with medium. High-osmolarity medium containing
508 a mix of exponentially-growing cells with and without repression of PBP1ab was then flushed in
509 the tunnel. The slide was incubated 15 min for cells to settle. Fresh medium was flushed again to
510 remove unattached cells. Then we took images of GFP and RFP fluorescence, to quantify the total
511 amount of GFP-PBP1b and RFP-PBP1a in each cell. This allowed to distinguish non-repressed cells
512 from repressed ones without ambiguity. We finally recorded phase-contrast images while the low-
513 osmolarity medium was flushed into the tunnel. Cells were tracked using a simple nearest-neighbor
514 algorithm, discarding the cells that went out of focus.

515 For osmotic shock resistance, cells were prepared in a similar manner, then growth in high-
516 osmolarity was monitored for 6 h in a plate reader. The plate was then centrifuged 2 min at 2000
517 x g, medium was discarded and low-osmolarity medium was added instead. Growth was then
518 monitored again for 4 h.

519 **Measurement of mreB-msfGFP motion**

520 Fluorescence images were generated on an inverted epi-fluorescence microscope (Nikon Ti-E)
521 equipped with a 100x phase contrast objective (CFI PlanApo LambdaDM100X 1.4NA, Nikon), a
522 solid-state light source (Spectra X, Lumencor Inc., Beaverton, OR), a multiband dichroic (69002bs,
523 Chroma Technology Corp., Bellows Falls, VT), and excitation (485/25) and emission (535/50) filters.
524 Images were acquired using a sCMOS camera (Orca Flash 4.0, Hamamatsu, Japan) with an effective
525 pixel size of 65 nm. For measurements of cell boundaries, we focused on cells based on the
526 phase-contrast signal. To track MreB-msfGFP spots moving at the bottom of the cell, we moved the
527 focal plane 250 nm below the central plane of cells. Images were taken every 2 s for a duration of
528 120 s.

529 Images were analyzed using a custom Matlab code as described previously described (*Wollrab*
530 *et al., 2019*). Briefly, images were first filtered in both space and time using a three-dimensional
531 Savitzky-Golay filter with a filter size of 3 pixels in xy-directions time 3 points along the temporal
532 dimension. Images were subsequently de-noised once more using a 2D-Gauss filter ($\sigma = 0.5$
533 pixels). Images were subsequently rescaled by a factor of 5 using spline interpolation to achieve
534 sub-pixel resolution. MreB spots were detected as local maxima inside the cell boundary obtained
535 by segmentation using the Morphometrics package (*Ursell et al., 2017*). MreB spots with intensity
536 higher than the cell background were considered for tracking. The local maxima were connected
537 to construct raw trajectories based on their distance at consecutive time points (*Teeffelen et al.,*
538 *2011*) with a maximal displacement during subsequent time frames of 3 pixels. After generating
539 the tracks, we applied a Gauss filter in time ($\sigma = 1.5$ time steps) in order to decrease spatial noise.
540 Tracks which have more than 7 localizations were considered for velocity distributions. Velocity is
541 calculated from single displacement vectors of the smoothed trajectories. Flux is then calculated
542 by summing over all end-to-end distances of smoothed tracks that are longer than 200 nm,
543 normalized by total duration of the movie (2 minutes for all movies) and total surface area of all
544 cells.

545 **Single-particle tracking of PBP1b**

546 Single particle tracking of sfGFP-PBP1b was performed in either of two custom-designed fluores-
547 cence microscopes, equipped with a custom-built temperature controlled chamber at 29°C or a
548 stage-top incubation chamber (Okolab). Prior to imaging cells were transferred to a pre-heated

549 1% agarose pad (Invitrogen) and covered with a pre-cleaned cover slip. Cover slips were cleaned
550 by bath sonication in a 1M KOH solution for 1h at 40C. Both microscopes were equipped with a
551 100x TIRF objective (Apo TIRF, 100x, NA 1.49, Nikon), three laser lines: 405 nm (Obis, Coherent), 488
552 nm (Sapphire, Coherent), 561 nm (Sapphire, Coherent), a dichroic beamsplitter (Di03-R488/561-t3-
553 25x36, Semrock) and a laser-line filter (NF561-18, Thorlabs). Shuttering of the 488 nm laser was
554 controlled with an acousto-optic tunable filter (AA Optoelectronics) or with shutters (Uniblitz, LS3
555 and TS6B, Vincent Associates). Images were acquired with an EMCCD camera (iXon Ultra, Andor).
556 All components were controlled and synchronized using MicroManager (*Edelstein et al., 2010*).
557 Images were acquired with exposure time and intervals of 60 ms for a duration of 20 s to 1 min.
558 To distinguish single molecules, this requires a photobleaching phase prior to image acquisition.
559 To that end, the sample was exposed to 488 nm laser in epifluorescence or HILO (highly inclined
560 and laminated optical sheet) mode. Since both modalities resulted in the same fractions of bound
561 molecules, the bleaching or illumination modality did apparently not bias towards either state of
562 molecules. After photobleaching, we either switched to TIR mode or remained in HILO mode for
563 image acquisition. Bleaching time is adjusted according to the level of PBP1b and illumination
564 intensity and was about 2 or 12 s for HILO and epi illumination, respectively. A longer bleaching
565 time of 10 or 25 s was required for GFP-PBP1b overexpression (Figure 4A, AV51 without repression).

566 To determine the bound fraction of GFP-PBP1b, we first segmented images using the brightfield
567 channel and standard image processing functions. PBP1b spots in fluorescence images were identi-
568 fied using the ThunderStorm plug-in for ImageJ (*Ovesný et al., 2014*) with wavelet filtering. The peak
569 detection threshold was equal to the standard deviation of the first wavelet levels of input image
570 (Wave.F1). Sub-pixel resolution was achieved by finding the center of a two-dimensional Gaussian
571 fitted to the intensity profile of each spot. Spots in subsequent frames were then connected using
572 the nearest-neighbor algorithm from TrackPy with a maximum step length of 500 nm (*Allan et al.,*
573 *2016*). To limit tracking mistakes, we discarded the frames where the peak density was too high
574 by only taking the last 30,000 peaks of each movie into account. The displacements were fit using
575 a two-state diffusion model from the SpotOn software package (*Hansen et al., 2018*), allowing to
576 recover the percentage of bound molecules, the peak localization precision and the free molecules'
577 diffusion constant. In the reference strain (strain AV44 with near-WT levels of PBP1a and PBP1b)
578 the diffusion constant of the "bound" molecules was left as a free parameter and found to be
579 compatible with immobilization of these molecules ($D_{\text{bound}} < 0.001 \mu\text{m}^2/\text{s}$, table 3, top). For the rest
580 of the analysis we fixed $D_{\text{bound}} = 0$ (table 3, bottom).

581 **Bocillin-labeling of the PBPs**

582 The bocillin-binding assay used to check the absence of non-fluorescent PBP1ab is similar to
583 what is used in (*Cho et al., 2016; Kocaoglu et al., 2012*). We prepared exponentially-growing cells
584 at $\text{OD}_{600} \approx 0.4$. We washed 1.8 ml of each culture in PBS, resuspended them in 200 μl PBS and
585 kept cultures on ice. We disrupted cells by sonication (FB120, Fisher Scientific) and centrifuged
586 them for 15 min at 4°C (21,000 g). We subsequently resuspended the pellet corresponding to the
587 membrane fraction in 50 μl PBS containing 15 μM fluorescently labelled Bocillin-FL (Invitrogen).
588 Membranes were incubated at 37°C for 30 min and washed once in 1 ml PBS. We centrifuged
589 the membranes for 15 min (21,000 g) and resuspended them in 50 μl PBS to remove unbound
590 Bocillin-FL. We measured the protein concentration of each sample with a colorimetric assay based
591 on the Bradford method (Bio-Rad) and loaded equal amounts of protein mixed with 4X Laemmli
592 buffer onto a 10% polyacrylamide gel (Miniprotean TGX, Bio-rad). We visualized the labelled proteins
593 with a Typhoon 9000 FLA imager (GE Healthcare) with excitation at 488 nm and emission at 530 nm.

594 **Acknowledgements**

595 We thank T. Bernhardt for providing the pH942 plasmid and W. Vollmer for providing the pBAD33-
596 pbp1b plasmid. We thank Richard Wheeler for assistance with peptidoglycan extraction and
597 chromatography analysis and to Eva Wollrab for help in the single-molecule tracking. This work

598 was supported by the European Research Council (ERC) under the Europe Union's Horizon 2020
599 research and innovation program [Grant Agreement No. (679980)], the French Government's In-
600 vestissement d'Avenir program Laboratoire d'Excellence "Integrative Biology of Emerging Infectious
601 Diseases" (ANR-10-LABX-62-IBEID), the Mairie de Paris "Emergence(s)" program, and the Volkswagen
602 Foundation.

603 References

- 604 **Allan D**, Caswell T, Keim N, van der Wel C. trackpy: Trackpy v0.3.2. Zenodo; 2016. [https://zenodo.org/record/](https://zenodo.org/record/60550)
605 [60550](https://zenodo.org/record/60550), doi: [10.5281/zenodo.60550](https://doi.org/10.5281/zenodo.60550).
- 606 **Auer GK**, Lee TK, Rajendram M, Cesar S, Miguel A, Huang KC, Weibel DB. Mechanical Genomics Identifies Diverse
607 Modulators of Bacterial Cell Stiffness. *Cell Systems*. 2016 Jun; 2(6):402–411. [http://www.sciencedirect.com/](http://www.sciencedirect.com/science/article/pii/S2405471216301818)
608 [science/article/pii/S2405471216301818](http://www.sciencedirect.com/science/article/pii/S2405471216301818), doi: [10.1016/j.cels.2016.05.006](https://doi.org/10.1016/j.cels.2016.05.006).
- 609 **Baba T**, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. Con-
610 struction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Molecu-
611 lar Systems Biology*. 2006 Feb; 2:2006.0008. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1681482/>, doi:
612 [10.1038/msb4100050](https://doi.org/10.1038/msb4100050).
- 613 **Banzhaf M**, van den Berg van Saparoea B, Terrak M, Fraipont C, Egan A, Philippe J, Zapun A, Breukink E, Nguyen-
614 Distèche M, den Blaauwen T, Vollmer W. Cooperativity of peptidoglycan synthases active in bacterial cell
615 elongation. *Molecular Microbiology*. 2012 Jul; 85(1):179–194. doi: [10.1111/j.1365-2958.2012.08103.x](https://doi.org/10.1111/j.1365-2958.2012.08103.x).
- 616 **Banzhaf M**, Yau HCL, Verheul J, Lodge A, Kritikos G, Mateus A, Hov AK, Stein F, Wartel M, Pazos M, Solovyova AS,
617 Savitski MM, den Blaauwen T, Typas A, Vollmer W. The outer membrane lipoprotein NlpI nucleates hydrolases
618 within peptidoglycan multi-enzyme complexes in *Escherichia coli*. *Microbiology*; 2019.
- 619 **Bertsche U**, Kast T, Wolf B, Fraipont C, Aarsman MEG, Kannenberg K, von Rechenberg M, Nguyen-Distèche
620 M, den Blaauwen T, Höltje JV, Vollmer W. Interaction between two murein (peptidoglycan) synthases, PBP3
621 and PBP1B, in *Escherichia coli*. *Molecular Microbiology*. 2006 Aug; 61(3):675–690. doi: [10.1111/j.1365-
622 2958.2006.05280.x](https://doi.org/10.1111/j.1365-2958.2006.05280.x).
- 623 **Bourmaud A**, Gallien S, Domon B. Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer:
624 Principle and applications. *PROTEOMICS*. 2016; 16(15-16):2146–2159. [https://onlinelibrary.wiley.com/doi/abs/](https://onlinelibrary.wiley.com/doi/abs/10.1002/pmic.201500543)
625 [10.1002/pmic.201500543](https://onlinelibrary.wiley.com/doi/abs/10.1002/pmic.201500543), doi: [10.1002/pmic.201500543](https://doi.org/10.1002/pmic.201500543).
- 626 **Bruderer R**, Bernhardt OM, Gandhi T, Xuan Y, Sondermann J, Schmidt M, Gomez-Varela D, Reiter L. Optimization
627 of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and
628 Reproducibility of Results. *Molecular & Cellular Proteomics*. 2017 Dec; 16(12):2296–2309. [https://www.
629 mcponline.org/content/16/12/2296](https://www.mcponline.org/content/16/12/2296), doi: [10.1074/mcp.RA117.000314](https://doi.org/10.1074/mcp.RA117.000314).
- 630 **Buda R**, Liu Y, Yang J, Hegde S, Stevenson K, Bai F, Pilizota T. Dynamics of *Escherichia coli*'s passive response to
631 a sudden decrease in external osmolarity. *Proceedings of the National Academy of Sciences of the United
632 States of America*. 2016; 113(40):E5838–E5846. doi: [10.1073/pnas.1522185113](https://doi.org/10.1073/pnas.1522185113).
- 633 **Caparrós M**, Pisabarro AG, de Pedro MA. Effect of D-amino acids on structure and synthesis of peptidoglycan in
634 *Escherichia coli*. *Journal of Bacteriology*. 1992 Sep; 174(17):5549–5559. [http://j.b.asm.org/lookup/doi/10.1128/
635 jb.174.17.5549-5559.1992](http://j.b.asm.org/lookup/doi/10.1128/jb.174.17.5549-5559.1992), doi: [10.1128/jb.174.17.5549-5559.1992](https://doi.org/10.1128/jb.174.17.5549-5559.1992).
- 636 **Caparrós M**, Quintela J, Pedro MAd. Variability of peptidoglycan surface density in *Escherichia coli*. *FEMS
637 Microbiology Letters*. 1994 Aug; 121(1):71–76. [https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1574-6968.
638 1994.tb07077.x](https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1574-6968.1994.tb07077.x), doi: [10.1111/j.1574-6968.1994.tb07077.x](https://doi.org/10.1111/j.1574-6968.1994.tb07077.x).
- 639 **Cho H**, Wivagg CN, Kapoor M, Barry Z, Rohs PDA, Suh H, Marto JA, Garner EC, Bernhardt TG. Bacterial cell
640 wall biogenesis is mediated by SEDS and PBP polymerase families functioning semi-autonomously. *Nature
641 Microbiology*. 2016 Sep; 1:16172. <http://www.nature.com/articles/nmicrobiol2016172>, doi: [10.1038/nmicro-
642 biol.2016.172](https://doi.org/10.1038/nmicrobiol.2016.172).
- 643 **Chung HS**, Yao Z, Goehring NW, Kishony R, Beckwith J, Kahne D. Rapid β -lactam-induced lysis requires successful
644 assembly of the cell division machinery. *Proceedings of the National Academy of Sciences*. 2009 Dec;
645 106(51):21872–21877. <https://www.pnas.org/content/106/51/21872>, doi: [10.1073/pnas.0911674106](https://doi.org/10.1073/pnas.0911674106).

- 646 **Cui L**, Vigouroux A, Rousset F, Varet H, Khanna V, Bikard D. A CRISPRi screen in *E. coli* reveals sequence-
647 specific toxicity of dCas9. *Nature Communications*. 2018 May; 9(1):1912. <https://www.nature.com/articles/s41467-018-04209-5>, doi: 10.1038/s41467-018-04209-5.
- 649 **Demarre G**, Guérout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marlière P, Mazel D. A new family of
650 mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPalpha)
651 conjugative machineries and their cognate *Escherichia coli* host strains. *Research in Microbiology*. 2005 Mar;
652 156(2):245–255. doi: 10.1016/j.resmic.2004.09.007.
- 653 **Dion MF**, Kapoor M, Sun Y, Wilson S, Ryan J, Vigouroux A, Teeffelen Sv, Oldenbourg R, Garner EC. *Bacillus*
654 *subtilis* cell diameter is determined by the opposing actions of two distinct cell wall synthetic systems. *Nature*
655 *Microbiology*. 2019 May; p. 1. <https://www.nature.com/articles/s41564-019-0439-0>, doi: 10.1038/s41564-019-0439-0.
- 657 **Dougherty TJ**, Kennedy K, Kessler RE, Pucci MJ. Direct quantitation of the number of individual penicillin-
658 binding proteins per cell in *Escherichia coli*. *Journal of Bacteriology*. 1996 Nov; 178(21):6110–6115. <https://j.b.asm.org/content/178/21/6110>, doi: 10.1128/jb.178.21.6110-6115.1996.
- 660 **Edelstein A**, Amodaj N, Hoover K, Vale R, Stuurman N. Computer Control of Microscopes Using μ Manager.
661 *Current Protocols in Molecular Biology*. 2010; 92(1):14.20.1–14.20.17. <https://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471142727.mb1420s92>, doi: 10.1002/0471142727.mb1420s92.
- 663 **Egan AJF**, Jean NL, Koumoutsi A, Bougault CM, Biboy J, Sassine J, Solovyova AS, Breukink E, Typas A, Vollmer
664 W, Simorre JP. Outer-membrane lipoprotein LpoB spans the periplasm to stimulate the peptidoglycan
665 synthase PBP1B. *Proceedings of the National Academy of Sciences of the United States of America*. 2014 Jun;
666 111(22):8197–8202. doi: 10.1073/pnas.1400376111.
- 667 **Emami K**, Guyet A, Kawai Y, Devi J, Wu LJ, Allenby N, Daniel RA, Errington J. RodA as the missing glycosyl-
668 transferase in *Bacillus subtilis* and antibiotic discovery for the peptidoglycan polymerase pathway. *Nature*
669 *Microbiology*. 2017 Mar; 2(3):16253. <https://www.nature.com/articles/nmicrobiol2016253>, doi: 10.1038/nmi-
670 crobiol.2016.253.
- 671 **Furchtgott L**, Wingreen NS, Huang KC. Mechanisms for maintaining cell shape in rod-shaped Gram-negative
672 bacteria. *Molecular Microbiology*. 2011; 81(2):340–353. <http://doi.wiley.com/10.1111/j.1365-2958.2011.07616.x>.
- 674 **Gallien S**, Duriez E, Crone C, Kellmann M, Moehring T, Domon B. Targeted Proteomic Quantification on
675 Quadrupole-Orbitrap Mass Spectrometer. *Molecular & Cellular Proteomics*. 2012 Dec; 11(12):1709–1723.
676 <https://www.mcponline.org/content/11/12/1709>, doi: 10.1074/mcp.O112.019802.
- 677 **Gan L**, Chen S, Jensen GJ. Molecular organization of Gram-negative peptidoglycan. *Proceedings of the National*
678 *Academy of Sciences*. 2008 Dec; 105(48):18953–18957. <https://www.pnas.org/content/105/48/18953>, doi:
679 10.1073/pnas.0808035105.
- 680 **Gray AN**, Egan AJF, Van't Veer IL, Verheul J, Colavin A, Koumoutsi A, Biboy J, Altelaar AFM, Damen MJ, Huang
681 KC, Simorre JP, Breukink E, den Blaauwen T, Typas A, Gross CA, Vollmer W. Coordination of peptidoglycan
682 synthesis and outer membrane constriction during *Escherichia coli* cell division. *eLife*. 2015 May; 4. doi:
683 10.7554/eLife.07118.
- 684 **Guzman LM**, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors
685 containing the arabinose PBAD promoter. *Journal of Bacteriology*. 1995 Jul; 177(14):4121–4130.
- 686 **Hansen AS**, Woring M, Grimm JB, Lavis LD, Tjian R, Darzacq X. Robust model-based analysis of single-particle
687 tracking experiments with Spot-On. *eLife*. 2018 Jan; 7:e33125. <https://elifesciences.org/articles/33125>, doi:
688 10.7554/eLife.33125.
- 689 **Hatfield D**, Hofnung M, Schwartz M. Genetic analysis of the maltose A region in *Escherichia coli*. *Journal of*
690 *Bacteriology*. 1969 May; 98(2):559–567.
- 691 **Jean NL**, Bougault CM, Lodge A, Derouaux A, Callens G, Egan AJF, Ayala I, Lewis RJ, Vollmer W, Simorre JP.
692 Elongated Structure of the Outer-Membrane Activator of Peptidoglycan Synthesis LpoA: Implications for
693 PBP1A Stimulation. *Structure*. 2014; <http://linkinghub.elsevier.com/retrieve/pii/S0969212614001464>.
- 694 **Kadokura H**, Beckwith J. Four cysteines of the membrane protein DsbB act in concert to oxidize its substrate
695 DsbA. *The EMBO journal*. 2002 May; 21(10):2354–2363. doi: 10.1093/emboj/21.10.2354.

- 696 **Kocaoglu O**, Lanning B, Cozy L, Calvo R, Kearns D, Carlson EE. Activity-Based Probes for Penicillin-Binding
697 Protein Imaging. *The FASEB Journal*. 2012 Apr; 26(1_supplement):1000.1–1000.1. [https://www.fasebj.org/doi/](https://www.fasebj.org/doi/abs/10.1096/fasebj.26.1_supplement.1000.1)
698 [abs/10.1096/fasebj.26.1_supplement.1000.1](https://www.fasebj.org/doi/abs/10.1096/fasebj.26.1_supplement.1000.1), doi: 10.1096/fasebj.26.1_supplement.1000.1.
- 699 **Lai GC**, Cho H, Bernhardt TG. The mecillinam resistome reveals a role for peptidoglycan endopeptidases in
700 stimulating cell wall synthesis in *Escherichia coli*. *PLOS Genetics*. 2017 Jul; 13(7):e1006934. [http://journals.](http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006934)
701 [plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006934](http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006934), doi: 10.1371/journal.pgen.1006934.
- 702 **Lambert MP**, Neuhaus FC. Mechanism of d-Cycloserine Action: Alanine Racemase from *Escherichia coli* W1.
703 *Journal of Bacteriology*. 1972 Jun; 110(3):978–987. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC247518/>.
- 704 **Lee TK**, Meng K, Shi H, Huang KC. Single-molecule imaging reveals modulation of cell wall synthesis dynamics in
705 live bacterial cells. *Nature Communications*. 2016; 7:13170. doi: 10.1038/ncomms13170.
- 706 **Lee TK**, Tropini C, Hsin J, Desmarais SM, Ursell TS, Gong E, Gitai Z, Monds RD, Huang KC. A dynamically assembled
707 cell wall synthesis machinery buffers cell growth. *Proceedings of the National Academy of Sciences of the*
708 *United States of America*. 2014 Mar; 111(12):4554–4559. doi: 10.1073/pnas.1313826111.
- 709 **Markovski M**, Bohrhunter JL, Lupoli TJ, Uehara T, Walker S, Kahne DE, Bernhardt TG. Cofactor bypass vari-
710 ants reveal a conformational control mechanism governing cell wall polymerase activity. *Proceedings of*
711 *the National Academy of Sciences of the United States of America*. 2016 Apr; 113(17):4788–4793. doi:
712 [10.1073/pnas.1524538113](https://doi.org/10.1073/pnas.1524538113).
- 713 **Meeske AJ**, Riley EP, Robins WP, Uehara T, Mekalanos JJ, Kahne D, Walker S, Kruse AC, Bernhardt TG, Rudner DZ.
714 SEDS proteins are a widespread family of bacterial cell wall polymerases. *Nature*. 2016 Sep; 537(7622):634–638.
715 <http://www.nature.com/nature/journal/v537/n7622/full/nature19331.html>, doi: 10.1038/nature19331.
- 716 **Mueller EA**, Egan AJ, Breukink E, Vollmer W, Levin PA. Plasticity of *Escherichia coli* cell wall metabolism
717 promotes fitness and antibiotic resistance across environmental conditions. *eLife*. 2019 Apr; 8:e40754.
718 <https://doi.org/10.7554/eLife.40754>, doi: 10.7554/eLife.40754.
- 719 **Nichols RJ**, Sen S, Choo YJ, Beltrao P, Zietek M, Chaba R, Lee S, Kazmierczak KM, Lee KJ, Wong A, Shales M,
720 Lovett S, Winkler ME, Krogan NJ, Typas A, Gross CA. Phenotypic landscape of a bacterial cell. *Cell*. 2011 Jan;
721 144(1):143–156. doi: 10.1016/j.cell.2010.11.052.
- 722 **Ouzounov N**, Nguyen JP, Bratton BP, Jacobowitz D, Gitai Z, Shaevitz JW. MreB Orientation Correlates with Cell
723 Diameter in *Escherichia coli*. *Biophysical Journal*. 2016 Sep; 111(5):1035–1043. [http://www.sciencedirect.com/](http://www.sciencedirect.com/science/article/pii/S000634951630580X)
724 [science/article/pii/S000634951630580X](http://www.sciencedirect.com/science/article/pii/S000634951630580X), doi: 10.1016/j.bpj.2016.07.017.
- 725 **Ovesný M**, Křížek P, Borkovec J, Švindrych Z, Hagen GM. ThunderSTORM: a comprehensive ImageJ plug-in for
726 PALM and STORM data analysis and super-resolution imaging. *Bioinformatics*. 2014 Aug; 30(16):2389–2390.
727 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207427/>, doi: 10.1093/bioinformatics/btu202.
- 728 **Paradis-Bleau C**, Markovski M, Uehara T, Lupoli TJ, Walker S, Kahne DE, Bernhardt TG. Lipoprotein Cofactors
729 Located in the Outer Membrane Activate Bacterial Cell Wall Polymerases. *Cell*. 2010 Dec; 143(7):1110–1120.
730 <http://www.sciencedirect.com/science/article/pii/S0092867410013590>, doi: 10.1016/j.cell.2010.11.037.
- 731 **Pazos M**, Peters K, Vollmer W. Robust peptidoglycan growth by dynamic and variable multi-protein com-
732 plexes. *Current Opinion in Microbiology*. 2017 Apr; 36:55–61. [https://linkinghub.elsevier.com/retrieve/pii/](https://linkinghub.elsevier.com/retrieve/pii/S1369527416301461)
733 [S1369527416301461](https://linkinghub.elsevier.com/retrieve/pii/S1369527416301461), doi: 10.1016/j.mib.2017.01.006.
- 734 **Peterson AC**, Russell JD, Bailey DJ, Westphall MS, Coon JJ. Parallel Reaction Monitoring for High Resolution
735 and High Mass Accuracy Quantitative, Targeted Proteomics. *Molecular & Cellular Proteomics*. 2012 Nov;
736 11(11):1475–1488. <https://www.mcponline.org/content/11/11/1475>, doi: 10.1074/mcp.O112.020131.
- 737 **García del Portillo F**, de Pedro MA. Penicillin-binding protein 2 is essential for the integrity of growing cells of
738 *Escherichia coli* ponB strains. *Journal of Bacteriology*. 1991 Jul; 173(14):4530–4532.
- 739 **García del Portillo F**, de Pedro MA, Joseleau-Petit D, D'Ari R. Lytic response of *Escherichia coli* cells to inhibitors
740 of penicillin-binding proteins 1a and 1b as a timed event related to cell division. *Journal of Bacteriology*. 1989
741 Aug; 171(8):4217–4221. doi: 10.1128/jb.171.8.4217-4221.1989.
- 742 **Ranjit DK**, Jorgenson MA, Young KD. PBP1B Glycosyltransferase and Transpeptidase Activities Play Different
743 Essential Roles during the De Novo Regeneration of Rod Morphology in *Escherichia coli*. *Journal of Bacteriology*.
744 2017; 199(7). doi: 10.1128/JB.00612-16.

- 745 **Singh SK**, SaiSree L, Amrutha RN, Reddy M. Three redundant murein endopeptidases catalyse an essential
746 cleavage step in peptidoglycan synthesis of *Escherichia coli* K12. *Molecular Microbiology*. 2012; 86(5):1036–
747 1051. <https://onlinelibrary.wiley.com/doi/abs/10.1111/mmi.12058>, doi: 10.1111/mmi.12058.
- 748 **St-Pierre F**, Cui L, Priest DG, Endy D, Dodd IB, Shearwin KE. One-Step Cloning and Chromosomal Integra-
749 tion of DNA. *ACS Synthetic Biology*. 2013 Sep; 2(9):537–541. <http://dx.doi.org/10.1021/sb400021j>, doi:
750 10.1021/sb400021j.
- 751 **Teeffelen Sv**, Wang S, Furchtgott L, Huang KC, Wingreen NS, Shaevitz JW, Gitai Z. The bacterial actin MreB
752 rotates, and rotation depends on cell-wall assembly. *Proceedings of the National Academy of Sciences*. 2011
753 Sep; 108(38):15822–15827. <https://www.pnas.org/content/108/38/15822>, doi: 10.1073/pnas.1108999108.
- 754 **Typas A**, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth
755 and morphology. *Nature Reviews Microbiology*. 2012 Feb; 10(2):123–136. [http://www.nature.com/nrmicro/](http://www.nature.com/nrmicro/journal/v10/n2/full/nrmicro2677.html)
756 [journal/v10/n2/full/nrmicro2677.html](http://www.nature.com/nrmicro/journal/v10/n2/full/nrmicro2677.html), doi: 10.1038/nrmicro2677.
- 757 **Typas A**, Banzhaf M, van den Berg van Saparoea B, Verheul J, Biboy J, Nichols RJ, Zietek M, Beilharz K, Kannenberg
758 K, von Rechenberg M, Breukink E, den Blaauwen T, Gross CA, Vollmer W. Regulation of Peptidoglycan Synthesis
759 by Outer-Membrane Proteins. *Cell*. 2010 Dec; 143(7):1097–1109. [http://www.sciencedirect.com/science/](http://www.sciencedirect.com/science/article/pii/S0092867410013607)
760 [article/pii/S0092867410013607](http://www.sciencedirect.com/science/article/pii/S0092867410013607), doi: 10.1016/j.cell.2010.11.038.
- 761 **Ursell T**, Lee TK, Shiomi D, Shi H, Tropini C, Monds RD, Colavin A, Billings G, Bhaya-Grossman I, Broxton M,
762 Huang BE, Niki H, Huang KC. Rapid, precise quantification of bacterial cellular dimensions across a genomic-
763 scale knockout library. *BMC Biology*. 2017 Feb; 15(1):17. <https://doi.org/10.1186/s12915-017-0348-8>, doi:
764 10.1186/s12915-017-0348-8.
- 765 **Vigouroux A**, Oldewurtel E, Cui L, Bikard D, van Teeffelen S. Tuning dCas9's ability to block transcription
766 enables robust, noiseless knockdown of bacterial genes. *Molecular Systems Biology*. 2018 Mar; 14(3):e7899.
767 <http://msb.embopress.org/lookup/doi/10.15252/msb.20177899>, doi: 10.15252/msb.20177899.
- 768 **Vollmer W**, Bertsche U. Murein (peptidoglycan) structure, architecture and biosynthesis in *Escherichia coli*.
769 *Biochimica et Biophysica Acta (BBA) - Biomembranes*. 2008 Sep; 1778(9):1714–1734. [http://www.sciencedirect.](http://www.sciencedirect.com/science/article/pii/S0005273607002210)
770 [com/science/article/pii/S0005273607002210](http://www.sciencedirect.com/science/article/pii/S0005273607002210), doi: 10.1016/j.bbamem.2007.06.007.
- 771 **Vollmer W**, Blanot D, De Pedro MA. Peptidoglycan structure and architecture. *FEMS Microbiology Reviews*.
772 2008 Mar; 32(2):149–167. <https://academic.oup.com/femsre/article/32/2/149/2683904>, doi: 10.1111/j.1574-
773 6976.2007.00094.x.
- 774 **Wheeler R**, Veyrier F, Werts C, Boneca IG. Peptidoglycan and Nod Receptor. In: Endo T, Seeberger PH, Hart
775 GW, Wong CH, Taniguchi N, editors. *Glycoscience: Biology and Medicine* Tokyo: Springer Japan; 2014.p. 1–10.
776 https://doi.org/10.1007/978-4-431-54836-2_147-1, doi: 10.1007/978-4-431-54836-2_147-1.
- 777 **Wientjes FB**, Nanninga N. On the role of the high molecular weight penicillin-binding proteins in the cell cycle of
778 *Escherichia coli*. *Research in Microbiology*. 1991 Jan; 142(2):333–344. [http://www.sciencedirect.com/science/](http://www.sciencedirect.com/science/article/pii/092325089190049G)
779 [article/pii/092325089190049G](http://www.sciencedirect.com/science/article/pii/092325089190049G), doi: 10.1016/0923-2508(91)90049-G.
- 780 **Wientjes FB**, Woldringh CL, Nanninga N. Amount of peptidoglycan in cell walls of gram-negative bacte-
781 ria. *Journal of Bacteriology*. 1991 Dec; 173(23):7684–7691. <https://jb.asm.org/content/173/23/7684>, doi:
782 10.1128/jb.173.23.7684-7691.1991.
- 783 **Wollrab E**, Özbaykal G, Vigouroux A, Cordier B, Simon F, Chaze T, Matondo M, van Teeffelen S. Transpepti-
784 dase PBP2 governs initial localization and activity of major cell-wall synthesis machinery in *Escherichia coli*.
785 *Microbiology*; 2019.
- 786 **Wong F**, Renner LD, Özbaykal G, Paulose J, Weibel DB, van Teeffelen S, Amir A. Mechanical strain sensing
787 implicated in cell shape recovery in *Escherichia coli*. *Nature Microbiology*. 2017 Sep; 2(9):17115. [https://](https://www.nature.com/articles/nmicrobiol2017115)
788 www.nature.com/articles/nmicrobiol2017115, doi: 10.1038/nmicrobiol.2017.115.
- 789 **Yao Z**, Kahne D, Kishony R. Distinct single-cell morphological dynamics under beta-lactam antibiotics.
790 *Molecular cell*. 2012 Dec; 48(5):705–712. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525771/>, doi:
791 10.1016/j.molcel.2012.09.016.
- 792 **Yousif SY**, Broome-Smith JK, Spratt BG. Lysis of *Escherichia coli* by Beta-Lactam Antibiotics: Deletion Analysis
793 of the Role of Penicillin-binding Proteins 1A and 1B. *Journal of General Microbiology*. 1985; 131(10):2839–
794 2845. <https://www.microbiologyresearch.org/content/journal/micro/10.1099/00221287-131-10-2839>, doi:
795 10.1099/00221287-131-10-2839.

796 **Zhao H, Patel V, Helmann JD, Dörr T.** Don't let sleeping dogmas lie: new views of peptidoglycan synthesis and
797 its regulation: New views on peptdigoglycan synthesis. *Molecular Microbiology*. 2017 Dec; 106(6):847–860.
798 <http://doi.wiley.com/10.1111/mmi.13853>, doi: 10.1111/mmi.13853.




Figure 1 - Supplement 1. Passage probability of the different CRISPR guides used in this study. This is measured by fluorescence microscopy in strain AV47 (LC69 HK022::P₁₂₇-*sfGfp*, λ::P₁₂₇-*mCherry*)/pCRRNacos for crRNA or pAV20 for sgRNA. When used to repress the RFP-PBP1a and GFP-PBP1b fusions in AV44, the repression level may be different because of genetic feedback. **A:** Repression of GFP and RFP by crRNAs expressed from the pcrRNacos vector. **B:** Repression of GFP and RFP by sgRNAs expressed from the pAV20 vector. See table 8 for the sequences of the guides. Relative fluorescence is expressed as a percentage of AV47/pAV20 G0-R0, i.e. without repression.




Figure 1 - Supplement 2. A: The RFP-PBP1a and GFP-PBP1b fusions are the only forms of aPBPs present in AV44. Fluorescent bocillin binds specifically to Penicillin Binding Proteins (PBP). The change in band intensity after repression by CRISPR does not reflect the change in fluorescence measured by microscopy for the same conditions, presumably because bocillin only labels potentially active molecules. All experiments are done in AV44/pcrRNacos with crRNA as annotated. **B and C:** Diameter of single cells at different levels of GFP-PBP1b (B) or RFP-PBP1a fusion (C), in strains AV100 (AV51 HK022::P_{Bad}-GFP-PBP1b) and AV101 (AV50 HK022::P_{Bad}-RFP-PBP1a) respectively. Different colors indicate different concentrations of arabinose, from 0% to 1%.




Figure 1 - Supplement 3. Quantification of sfGFP-PBP1b by semi-quantitative SDS-page.

A: Purified sfGFP-6xHis. Left: Elution fraction loaded in a 4-20% acrylamide gel stained with Coomassie blue. The predicted sfGFP-6xHis molecular weight is $\approx 28,42$ kDa. Right: visualization of the in-gel fluorescent signal. The higher molecular weight bands probably correspond to sfGFP oligomers as they are also detected on purified sfGFP. **B:** 4-20% acrylamide gel with decreasing amounts of purified sfGFP-6xHis (first 3 lanes), followed with whole cell extracts of LC69, AV44 or AV51 with pAV20 as annotated. Approximately 30 μ g of proteins were loaded. sfGFP-PBP1b isoforms: isoform α (predicted molecular weight 94,32 kDa, 121,1 kDa tagged with sfGFP), isoform μ (predicted molecular weight 88,91 kDa, 115,69 kDa tagged with sfGFP). Top: GFP fluorescence measurement. Bottom: Coomassie blue staining. There is no signal of the purified sfGFP-6xHis fusion protein because the amount loaded is probably below visualization limit with the Coomassie blue method.




Figure 1 - Supplement 4. Residual PBP1a and PBP1b levels in response to CRISPR-based repression, measured by fluorescence microscopy.

Left: The same CRISPR guides produce different repression strength on GFP, depending on whether it is expressed constitutively in AV47 (186::P_{Tet75}-dCas9, HK022::P₁₂₇-*sfGfp*, λ ::P₁₂₇-*mcherry*) or fused to PBP1b in the native locus (AV44). **Right:** Same experiment on the RFP-PBP1a fusion, on AV44, showing no evidence for feedback. sgRNAs are expressed from pAV20 with sgRNA G0, R0, G14 or R18 as annotated. In each case, relative fluorescence is expressed as a percentage of the fluorescence of the same strain carrying the pAV20 G0-R0 control plasmid, i.e. without repression.




Figure 1 - Supplement 5. Dimensions of individual cells before lysis due to PBP1ab repression.

Strain: AV44/pAV20 G20-R20. Imaging starts 4h45 after the induction of the CRISPR system. Cell length and cell diameter are normalized with respect to the dimensions of the cell in the first frame of the movie. Solid lines are living cells, dashed lines are lysed cells (phase-bright). Colors are arbitrary.




Figure 1 - Supplement 6. HPLC analysis of the peptidoglycan after digestion by mutanolysin in LC69 (WT) and AV44/pAV20 G14-R20 (Repressed), a.u.: arbitrary units.




Figure 2 - Supplement 1. Amount of incorporated ^3H -mDAP per optical density as a function of time. Strains are AV84 (AV44 $\Delta lysA$)/pAV20 G0-R0, AV84/pAV20 G14-R20, AV84/pAV20 G20-R0 and AV105 (AV84 $\Delta PBP1b$)/pAV20 G0-R0, from left to right. Colored curves are exponential fits (see methods) to the raw measurements (open symbols). Each color represents one biological replicate. a.u.: arbitrary units, corresponding to CPM per optical density units.




Figure 2 - Supplement 2. Growth curves before and after osmotic shock.

Strains are AV44 ("WT") or AV93 (AV44 $\Delta mscSL$) (" $\Delta mscSL$ ") with pAV20 G0-R0 ("High levels PBP1ab") or pAV20 G14-R20 ("Low levels PBP1ab"). Vertical lines mark the time of centrifugation, medium removal and resuspension in a medium of lower osmolarity. Optical densities are normalized with respect to the value at the time of the medium shift. Each curve is one biological replicate. Experiment done in a plate-reader. OD: Optical density.




Figure 3 - Supplement 1. Effect of depletion of peptidoglycan precursors measured by MreB motion. (A, B): Probability distributions of the instantaneous velocity of MreB-msfGFP measured upon D-cycloserine treatment using strain B172 (MG1655 *mreB* \leftrightarrow *mreB*-msfGFP) (A), or during depletion of mDAP in mDAP auxotroph, B176 (MG1655 *asd-1*, *mreB* \leftrightarrow *mreB*-msfGFP) (C). Measurements carried out in LB. (B, C): Flux of MreB-msfGFP corresponding to the experiments in A, B, respectively. Flux is calculated as sum of track end-to-end distances divided by total cell area and movie duration.




Figure 3 - Supplement 2. D-cycloserine sensitivity at different PBP1b levels and drug concentrations
 Growth curves of B150 (Δ PBP1b)/pBC03 (pBAD33- P_{Bad} -PBP1b) induced with arabinose ("Induced"), not induced ("Not induced") or MG1655 ("WT"), during treatment with three different concentrations of D-cycloserine (0.005 mM to 1 mM). Measurements performed in plate reader. OD: Optical density.




Figure 4 - Supplement 1. Tracking of single molecules using the Spot-On tool.

Left: Sample tracks corresponding to bound and diffusive GFP-PBP1b molecules, overlaid on a brightfield image using strain AV44/pCRRNAcos G10-R18 (280% PBP1a, 130% PBP1b). **Right:** Observed and fit distributions of particle jump lengths over n time steps. Distributions shown for one replicate of strain AV44/pCRRNAcos G10-R18.




Figure 4 - Supplement 2. Localization of bound molecules

(A-B): Position of bound molecules with respect to a normalized coordinate system measured in AV51 (AV44 Δ PBP1a)/pCRRNAcos with crRNA G10 (130% PBP1b with respect to WT). Bound molecules were identified according to their MSD ($\text{MSD} < (50\text{nm})^2$). In 67 cells we found 195 tracks. Tracks were assigned to a cell if the distance from the axis of the cell was below $0.5 \mu\text{m}$. The average length of cells was $3.7 \mu\text{m}$. (A) scatter plot of bound sites with normalized longitudinal coordinate. (B) histogram along x of normalized cell.




Figure 4 - Supplement 3. Effect of D-cycloserine treatment in minimal media.

A: Cell length during D-cycloserine treatment (1 mM) under the microscope using strain AV51 (AV44 Δ BPB1a)/pAV20 in minimal medium with glucose and 0.01% casamino acids. Length is normalized by the length of the same cell at $t = 0$. Solid lines: growing cells, dashed lines: phase-bright, lysing cells. **B:** Growth curves of AV51 during D-cycloserine treatment (1 mM; same medium as in A). Lines represent three biological replicates. OD: Optical density. **C-F:** MreB rotation during D-cycloserine treatment (C,E) and during recovery from a 30 min period of D-cycloserine treatment (D,F) using strain B172 (MG1655 $mreB \leftrightarrow mreB$ -msfGFP) grown in minimal medium as in A and analyzed as in Figure 3 - Supplement 1.




Figure 4 - Supplement 4. Free diffusion coefficient (D_{free}) during D-cycloserine treatment and recovery. (A-B): D_{free} of GFP-PBP1b at different times during 1 mM D-cycloserine treatment (A) and during recovery from 30 min of 1 mM D-cycloserine treatment (B) in the strain AV51/pCRRNAcos G10-RØ. Corresponding bound fractions provided in Figure 4 (D-E).

799 **Supplementary information**

800 **Quantification of GFP-PBP1b by SDS-page**

801 A sfGFP-His6 fusion protein was purified in this study to be used as an internal standard for the
802 semi-quantitative sfGFP-PBP1b SDS-page. The sfGFP-6xHis fusion was expressed and purified from
803 a BL21(DE3) *E. coli* strain. A 10 ml LB preculture containing carbenicillin (100 µg/ml) was inoculated
804 from a freshly transformed colony and grown at 37°C until an OD₆₀₀≈0.6. This culture was diluted
805 1:100 into 500 ml fresh pre-warmed LB containing carbenicillin (100 µg/ml) and grown at 37°C to
806 an OD₆₀₀≈0.6. At this time point, the expression was induced by the addition of 1 mM of IPTG and
807 the culture was incubated at 20°C overnight. The next day, the culture was cooled for 15 min at
808 4°C and the cells were recovered by centrifugation (4,000 × g) at 4°C for 15 min. Cell pellets were
809 resuspended in 12,5 ml of lysis buffer (20 mM Tris-HCl pH 8, 100 mM NaCl, 5 mM 2-mercaptoethanol,
810 20 mM imidazole, 1 mM PMSF) and stored at -80°C. Cells were thawed, benzonase (E1014, Millipore)
811 and lysozyme (L6876, Sigma) were added (respectively 500 units and 0,5 mg/ml) and cells were
812 disrupted by sonication on ice. Cell debris and membranes were pelleted by centrifugation at
813 40,000 × g for 1 hour at 4°C. In parallel, a 2 ml aliquot of Ni-NTA agarose resin slurry (#25214,
814 ThermoFisher), corresponding to a 1 ml beads volume, was equilibrated using 50 ml of buffer
815 with 20 mM of imidazole. The soluble protein extract was incubated with the beads for 1 hour
816 on a wheel at 4°C and loaded on a gravity column. The beads were extensively washed on the
817 column using 50 ml of buffer (20 mM Tris-HCl pH 8, 500 mM NaCl, 5 mM 2-mercaptoethanol, 50 mM
818 imidazole, 10% glycerol). Bound sfGFP-6xHis proteins were eluted in 10 ml buffer (20 mM Tris-HCl
819 pH 8, 500 mM NaCl, 5 mM 2-mercaptoethanol, 120 mM imidazole, 10% glycerol). Fractions of 1
820 ml were collected and their concentration was estimated using a Bradford-based Protein Assay
821 (Bio-Rad) according to the instructions. The purity of elution fractions was also estimated by loading
822 5 µl on a 4-20 percent polyacrylamide gel (Miniprotean TGX, Bio-rad) stained with Coomassie blue
823 and scanned with a Typhoon 9000 FLA imager (GE Healthcare) to detect GFP signal (473 nm laser,
824 excitation wavelength 489 nm, emission 508 nm) (figure 1 - Supplement 3A).

825 In order to estimate the copy numbers of sfGFP-PBP1b per cell, three independent cell extract
826 preparations of AV44 pAV20-GØ-RØ (non-repressed), AV44 pAV20 G14-R20 and AV51 (ΔPBP1a)
827 pAV20 G14-R20 were analyzed by fluorescence gel-based assay. Cells were grown overnight in LB at
828 30°C and diluted 1/100 into 40 ml of LB with 100 ng/ml anhydrotetracycline. Three independent
829 cultures, for each strain, were grown at 30°C to an OD₆₀₀ approximately of 0.3 and the colony
830 forming units (cfu) of each culture were determined by plating serial dilutions on LB plates. Cells
831 were harvested by centrifugation, resuspended in 200 µl of PBS 1x. Cells were disrupted by
832 sonication and protein concentrations were determined using a Bradford-based Protein Assay
833 (5000006, Bio-Rad) according to the instructions. 150 µl of the total cell extract was mixed with
834 25 µl of Laemmli sample buffer 4X (#1610747, Bio-Rad). Cell extracts were flash-frozen in liquid
835 nitrogen and stored at -80°C. To determine the amount of PBP1b in each of the extracts, normalized
836 amounts of total protein were loaded on 4-20 % polyacrylamide gels (Miniprotean TGX, Bio-rad)
837 together with increasing amounts of purified sfGFP-6xHis (same sfGFP used for PBP1b tagging).
838 After migration, the gel was stained with Coomassie blue and scanned for fluorescence as detailed
839 above. A standard curve plotting integrated signal intensity versus protein concentration was
840 generated for the purified sfGFP-6xHis and was used to determine the number of molecules of
841 sfGFP-PBP1b loaded on the gel for each cell extract. The cell number determined for the initial cell
842 cultures were then used to calculate the number of PBP1b molecules per cell.

Table 1. Levels of PBP1a expressed from different cassettes, and repressed using different sgRNA or crRNA. Ø: Control guides producing no repression. n.d.: not determined. DIA: Data-Independent Acquisition. PRM: Parallel Reaction Monitoring. * Levels relative to LC69 are obtained by multiplying the levels relative to AV44 by the levels obtained by DIA for AV44, with propagated error.

Relative quantification of PBP1a						
Strain	Promoter	System	Guide	Fluorescence (% of AV44)	Fluorescence (% of LC69*)	DIA (%)
LC69	Wild-type			n.d.	n.d.	100
AV44	Native fusion	sgRNA	R20	n.d.	n.d.	20±2
AV44	Native fusion	crRNA	R20	3±4	43±56	n.d.
AV44	Native fusion	crRNA	R18	21±4	278±139	n.d.
AV44	Native fusion	crRNA	R11	46±6	620±298	n.d.
AV44	Native fusion	crRNA	RØ	100±7	1337±622	1337±615
AV63	P _{Bad}	crRNA	R18	166±14	1549±786	n.d.
AV63	P _{Bad}	crRNA	R11	355±22	4750±2204	n.d.
AV63	P _{Bad}	crRNA	RØ	691±50	9243±4304	n.d.

Relative and absolute quantification of PBP1b								
Strain	Promoter	System	Guide	Fluorescence (% of AV44)	Fluorescence (% of LC69*)	DIA (%)	SDS-page (copy/cell)	PRM (copy/cell)
LC69	Wild-type			n.d.	n.d.	100	n.d.	166±28
AV44	Native fusion	sgRNA	G20	1.0±0.04	3.8±0.4	n.d.	n.d.	n.d.
AV44	Native fusion	sgRNA	G14	6.6±0.79	24±2.9	27±2	40±5	56±17
AV44	Native fusion	crRNA	G20	4.1±2.0	15±7.6	n.d.	n.d.	n.d.
AV44	Native fusion	crRNA	G14	12±3.1	44±12	n.d.	n.d.	n.d.
AV44	Native fusion	crRNA	G10	36±2.8	131±15	n.d.	n.d.	n.d.
AV44	Native fusion	crRNA	GØ	100±5.4	367±38	367±32	688±115	547±52
AV58	P _{Bad}	crRNA	GØ	509±57	1870±265	n.d.	n.d.	n.d.

Table 2. Fit parameters for the mDAP incorporation experiment. The incorporated ³H-mDAP per cell is fit with formula $k_{in}/\gamma + k_{out}(1 - e^{-t*(\gamma+k_{out})t})$, where k_{in} is the rate of mDAP incorporation, and k_{out} the rate of turn-over, γ the growth rate and t the time (min). γ was measured to be 0.0069 min⁻¹, k_{out} was fit jointly for all curves and is equal to 0.012 min⁻¹. Standard errors for k_{in} is also indicated.

Strain	PBP1a level (%)	PBP1b level (%)	k_{in} (a.u. / min)
Non-repressed	1300	370	786±16
Non-repressed	1300	370	943±27
Non-repressed	1300	370	886±59
G14-R2	20	30	873±77
G14-R2	20	30	760±67
G14-R2	20	30	863±46
G20-RØ	1300	4	678±32
G20-RØ	1300	4	706±45
ΔmrcB	1300	0	547±51
ΔmrcB	1300	0	613±55

Table 3. Fit parameters for PBP1b single-molecule tracking. Diffusion constants D_{free} and D_{bound} are in $\mu\text{m}^2/\text{s}$. The peak localization uncertainty σ is in μm . Over: over-expression. WT: approximately wild-type level. Δ : deletion.

Fit with 4 degrees of freedom (diffusion constants of two fractions, fraction of bound molecules, and localization precision σ), on a strain with wild-type levels of PBP1ab:

PBP1a	PBP1b	MepS	LpoB	% bound	D_{free}	D_{bound}	σ	Tracks number
WT	WT	WT	WT	18.5	0.0681	0.007377	0.0335	8321
WT	WT	WT	WT	21.1	0.0537	0.000414	0.0376	6012
WT	WT	WT	WT	21.5	0.0598	0.002609	0.0349	7156

Fit with 3 degrees of freedom (diffusion constant of diffusive fraction, bound fraction, localization precision), while D_{bound} is set to zero:

PBP1a	PBP1b	MepS	LpoB	% bound	D_{free}	D_{bound}	σ	Tracks number
1300%	30%	WT	WT	16.88	0.0784	0	0.0437	9547
1300%	30%	WT	WT	12.95	0.0616	0	0.0392	6986
1300%	30%	WT	WT	18.31	0.0751	0	0.0403	7620
Δ	370%	WT	WT	18.03	0.0790	0	0.0547	10692
Δ	370%	WT	WT	18.62	0.0681	0	0.0484	10806
Δ	370%	WT	WT	20.17	0.0768	0	0.0468	9622
Δ	WT	WT	WT	20.13	0.0864	0	0.0491	13417
Δ	WT	WT	WT	23.95	0.0721	0	0.0424	7393
Δ	WT	WT	WT	25.50	0.0752	0	0.0457	10016
Δ	30%	WT	WT	44.57	0.0700	0	0.0430	10467
Δ	30%	WT	WT	51.14	0.0757	0	0.0396	5371
Δ	30%	WT	WT	41.01	0.0722	0	0.0416	10301
WT	WT	WT	Δ	7.24	0.0579	0	0.0441	9147
WT	WT	WT	Δ	10.38	0.0717	0	0.0342	7470
WT	WT	WT	Δ	16.70	0.0622	0	0.0416	10374
WT	WT	WT	Over.	25.13	0.0517	0	0.0403	8280
WT	WT	WT	Over.	35.96	0.0457	0	0.0336	5107
WT	WT	WT	Over.	34.55	0.0450	0	0.0382	7061
WT	WT	WT	WT	11.00	0.0578	0	0.0373	8321
WT	WT	WT	WT	20.75	0.0528	0	0.0384	6012
WT	WT	WT	WT	19.08	0.0543	0	0.0393	7156
20%	30%	Over.	WT	46.94	0.0566	0	0.0380	9116
20%	30%	Over.	WT	52.10	0.0628	0	0.0341	6137
20%	30%	Over.	WT	40.06	0.0701	0	0.0355	8980
20%	30%	WT	WT	34.63	0.0623	0	0.0334	6736
20%	30%	WT	WT	41.81	0.0706	0	0.0346	7313
20%	30%	WT	WT	38.19	0.0626	0	0.0325	7195

Table 4. Strains used in this study.

Strain	Genotype	Construction
LC69	186::P _{Tet75} - <i>dcas9</i>	(Cui et al., 2018)
AV03	186::P _{Tet} - <i>dcas9</i> , HK022::P ₁₂₇ , λ::P ₁₂₇	Vigouroux et al. (2018)
AV04	186::P _{Tet} - <i>dcas9</i> , λ::P ₁₂₇ - <i>mcherry</i>	Vigouroux et al. (2018)
AV08	186::P _{Tet} - <i>dcas9</i> , <i>mrdA</i> :: <i>mcherry-mrdA</i>	Vigouroux et al. (2018)
AV44	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i>	LC69→pAV42→pAV43
AV47	186::P _{Tet75} - <i>dcas9</i> , HK022::P ₁₂₇ - <i>sfgfp</i> , λ::P ₁₂₇ - <i>mcherry</i>	AV03→P1 (pLC143)
AV50	186::P _{Tet75} - <i>dcas9</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>mrcB</i>	AV44→P1 (Keio Δ <i>mrcB</i>)
AV51	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , Δ <i>mrcA</i>	AV44→P1 (Keio Δ <i>mrcA</i>)
AV58	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , Δ <i>mrcA</i> , HK022::P _{Bad} - <i>sfgfp-mrcB</i>	AV51→pAV71
AV63	186::P _{Tet75} - <i>dcas9</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>mrcB</i> , HK022::P _{Bad} - <i>mCherry-mrcA</i>	AV50→pAV77
AV80	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>pbpC</i> , Δ <i>mtgA</i> , Δ <i>mscS</i> , Δ <i>mscL</i>	AV44→P1 (Keio Δ <i>mtgA</i>)
AV84	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>pbpC</i> , Δ <i>mtgA</i> , Δ <i>lysA</i>	AV80→P1 (Keio Δ <i>lysA</i>)
AV88	186::P _{Tet75} - <i>dcas9</i> , <i>mreB</i> :: <i>mreB-msfGFP</i>	Dion et al. (2019)
AV93	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>pbpC</i> , Δ <i>mtgA</i> , Δ <i>mscS</i> , Δ <i>mscL</i>	AV80→P1 (Keio Δ <i>mscS</i>)
AV100	186::P _{Tet75} - <i>dcas9</i> , Δ <i>mrcA</i> , Δ <i>mrcB</i> , HK022::P _{Bad} - <i>sfgfp-mrcB</i>	AV58→P1 (Keio Δ <i>mrcB</i>)
AV101	186::P _{Tet75} - <i>dcas9</i> , Δ <i>mrcA</i> , Δ <i>mrcB</i> , HK022::P _{Bad} - <i>mcherry-mrcA</i>	AV63→P1 (Keio Δ <i>mrcA</i>)
AV105	186::P _{Tet75} - <i>dcas9</i> , Δ <i>mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>pbpC</i> , Δ <i>mtgA</i> , Δ <i>lysA</i>	AV93→P1 (Keio Δ <i>mrcB</i>)
AV109	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>lpoA</i>	AV44→P1 (Keio Δ <i>lpoA</i>)
AV110	186::P _{Tet75} - <i>dcas9</i> , <i>mrcB</i> :: <i>msfgfp-mrcB</i> , <i>mrcA</i> :: <i>mcherry-mrcA</i> , Δ <i>lpoB</i>	AV44→P1 (Keio Δ <i>lpoB</i>)
NO34	<i>mreB</i> :: <i>mreB-msfgfp_{sw}-kanR</i>	Ouzounov et al. (2016)
B150	Δ <i>mrcB</i>	MG1655→P1 (Keio Δ <i>mrcB</i>)
B151	FB83, <i>asd-1</i>	Teeffelen et al. (2011)
B157	FB83, <i>asd-1</i> , Δ <i>mrcB</i>	B151→P1 (Keio Δ <i>mrcB</i>)
B172	<i>mreB</i> :: <i>mreB-msfgfp_{sw}-kanR</i>	MG1655→P1 (NO34)
B174	Δ <i>mrcB</i> , <i>mreB</i> :: <i>mreB-msfgfp_{sw}-kanR</i>	B150→P1 (NO34)
B176	FB83, <i>asd-1</i> , <i>mreB</i> :: <i>mreB-msfgfp_{sw}-kanR</i>	B151→P1 (NO34)
B178	FB83, <i>asd-1</i> , Δ <i>mrcB</i> , <i>mreB</i> :: <i>mreB-msfgfp_{sw}-kanR</i>	B157→P1 (NO34)

Table 5. Plasmids used in this study. The fragments "D" are obtained by enzymatic digestions, while the fragments "R" are obtained by PCR amplification. Details about the fragments can be found in table 6. MG1655 is a gift from Didier Mazel.

Plasmid	Description	Assembly or reference
pAV10	P _{PhIF} - <i>Cas9</i> and sgRNA cutting <i>cat</i>	(Vigouroux et al., 2018)
pE-FLP	Flippase	(St-Pierre et al., 2013)
pAV20	Cloning vector for 2 sgRNAs	(Dion et al., 2019)
pLC143	Integrate P _{Tet75} - <i>dCas9</i> in attB ₁₈₆	(Cui et al., 2018)
pAV42	Integrate <i>msfgfp-mrcB</i> in native locus	R62 + R63 + R27
pAV43	Integrate <i>mcherry-mrcA</i> in native locus	R64 + R65 + R66 + R23
pHC942	Template for <i>msfgfp-mrcB</i>	(Cho et al., 2016)
pAV71	Integrate P _{Bad} - <i>msfgfp-mrcB</i> in attB _{HK022}	D1+R97+R98
pAV77	Integrate P _{Bad} - <i>mcherry-mrcA</i> in attB _{HK022}	D1+R97+R105
pAV93	P _{T7} - <i>msfGFP</i>	R119+R120
pAM238	Spec-resistant vector with P _{Lac}	(Kadokura and Beckwith, 2002)
pBC01	pAM238-P _{Lac} - <i>lpoB</i>	D10+R126
pBC02	pAM238-P _{Lac} - <i>mepS</i>	D11+R127
pBC03	pBAD33-P _{Ara} - <i>mrcB</i>	(Gray et al., 2015)

Table 6. Fragments used to assemble the plasmids.

Digestion	Enzyme 1	Enzyme 2	Substrate	Reference
D1	EcoRI	PstI	pIT5-KH	<i>(St-Pierre et al., 2013)</i>
D10	SacI	BamHI	pAM238	<i>(Kadokura and Beckwith, 2002)</i>
D11	SacI	XbaI	pAM238	<i>(Kadokura and Beckwith, 2002)</i>
PCR	Primer 1	Primer 2	Template	Reference
R23	V101	V102	pSW23t	<i>(Demarre et al., 2005)</i>
R27	V109	V110	pSW23t	<i>(Demarre et al., 2005)</i>
R62	V111	V234	MG1655	
R63	V233	V116	pHC942	<i>(Cho et al., 2016)</i>
R64	V103	V238	MG1655	
R65	V235	V236	AV04	<i>(Vigouroux et al., 2018)</i>
R66	V237	V108	MG1655	
R97	V317	V318	pBAD30	<i>(Guzman et al., 1995)</i>
R98	V319	V320	AV44	This work
R105	V322	V341	AV44	This work
R119	V375	V376	AV44	This work
R120	V377	V378	pET23a	Novagen
R126	BC1	BC2	MG1655	
R127	BC3	BC4	MG1655	

Table 7. Oligonucleotides used to make the fragments in table 6.

Oligo	Sequence
V101	TGGTGGCTGGCACAAGTGCCTCCAGCTTTTGTCCCTTTAGTGAGGGTTAATTGC
V103	TGATATCGAATTCCTGCAGCCGCGTAATGCTTGTGTCAG
V109	AAGGTAAGATCTCTCCGGCTCCAGCTTTTGTCCCTTTAGT
V111	GATATCGAATTCCTGCAGCCCGAAGAGCCGCCACGGAT
V233	GATGACTATGAGGATGAAGAACCGATGAGTAAAGGTGAAGAACTGTTACCCGGTG
V235	ATGAACTAAATGGGAAATTTCCAGTGGTTTCCAAGGGCGAGGAG
V237	ATGGATGAGCTGTACAAAGGATCCAAGTTCGTAAGTATTTTTGATCCTTGACG
V317	CGCCATAAACTGCCAGGAATTGGGGATCGGGTTACCAATTATGACAACTTGACGGCTAC
V319	TCGCAACTCTACTGTTTCTCCATACCCGTGCGGAGAAAAAGCATGGCCGG
V322	AGGCGCCATGCATCTCGAGGCATGCCTGCATAATCAGAACAATTCCTGTGCCTCG
V315	GGTACCGGGCCCCCTCGAGGTCGATTTGAGTAGAAAACGCAGCGGATGCAGGCCGTCGTTACCCAAG
V316	TGCTGCCGGTGCCATGCCCTCCGGAACCGGTGGAGAGGACGGTCAGCTGG
V317	CGCCATAAACTGCCAGGAATTGGGGATCGGGTTACCAATTATGACAACTTGACGGCTAC
V318	CGGGTATGGAGAAACAGTAGAGAG
BC1	TATATAGAGCTCAGGAGGAATTCACCATGACAAAAATGAGTCGCTACG
BC2	TATATAGGATCCTTATTGCTGCGAAACGGC
BC3	TGACTGACGAGCTCAGGAGGAATTCACCATGGTCAAATCTCAACCGATTTTG
BC4	GTCAGTCATCTAGATTAGCTGCGGCTGAGAACCCG

Table 8. Oligonucleotides inserted in the pAV20 cloning vector to make plasmids expressing two single-guide RNAs, one against GFP (sfGFP) and one against RFP (mCherry). The capital letters indicate the final sequence of the CRISPR guide. After guide insertion, the plasmids are called “pAV20-GX-RY” with *X* the complementarity against GFP and *Y* the complementarity against RFP.

Name	Oligo	Target	Complementarity	DNA strand	Sequence
G20	V272	sfGFP	20 bp	Forward	ctagtCACCACGAACAGAGAATTTGgt
G14	V273	sfGFP	14 bp	Forward	ctagtGTGGTGGAACAGAGAATTTGgt
G10	V274	sfGFP	10 bp	Forward	ctagtGTGGTGCTTGAGAGAATTTGgt
GØ	V275	sfGFP	5 bp	Forward	ctagtGTGGTGCTTGTCTCTATTTGgt
R20	V276	mCherry	20 bp	Forward	tagtTCTGGGTGCCTTCATACGGA
R18	V277	mCherry	18 bp	Forward	tagtAGTGGGTGCCTTCATACGGA
R11	V278	mCherry	11 bp	Forward	tagtAGACCCACGCTTCATACGGA
RØ	V279	mCherry	5 bp	Forward	tagtAGACCCACGGAAGTAACGGA
G20	V280	sfGFP	20 bp	Reverse	taaaacCAAATTCTCTGTTCCGTGGTga
G14	V281	sfGFP	14 bp	Reverse	taaaacCAAATTCTCTGTTCCACCACa
G10	V282	sfGFP	10 bp	Reverse	taaaacCAAATTCTCTCAAGCACCACa
GØ	V283	sfGFP	5 bp	Reverse	taaaacCAAATAGAGACAAGCACCACa
R20	V284	mCherry	20 bp	Reverse	aaacTCCGTATGAAGGCACCCAGA
R18	V285	mCherry	18 bp	Reverse	aaacTCCGTATGAAGGCACCCACT
R11	V286	mCherry	11 bp	Reverse	aaacTCCGTATGAAGCGTGGGTCT
RØ	V287	mCherry	5 bp	Reverse	aaacTCCGTACTTCCGTGGGTCT